session tracker 2 0 1 4 Pre-meeting Courses:
session 2 0 1 4 tracker Pre-meeting Courses: Friday, November 14 – Saturday, November 15, 2014 Annual Scientific Sessions: Saturday, November 15 – Wednesday, November 19, 2014 Exhibits: Sunday, November 16 – Tuesday, November 18, 2014 Great Meetings Come from Great Ideas! CALL FOR PROPOSALS: 4VCNJUZPVSTFTTJPOJEFBPSTUVEZHSPVQUPQJD GPSUIF"$3"3)1"OOVBM.FFUJOHBU ACRannualmeeting.org50%": We are looking for proposals that: t3FøFDUDMJOJDBMJOOPWBUJPOBOEDVUUJOHFEHFSFTFBSDI t$POWFZCFTUQSBDUJDFT t1SFTFOUFWJEFODFCBTFENFEJDJOF t4UJNVMBUFEJTDVTTJPOBOEDIBMMFOHFNJOETFUT Tell us about learning models that: t"EESFTTDIBMMFOHFTJOZPVSBSFBPGQSBDUJDF Relevant topics may include: t5FDIOPMPHJDBMBEWBODFTJNQBDUJOHQSBDUJDF t8PSMEXJEFUSFOETJOQBUJFOU DBSF t0VUDPNFTBTTFTTNFOUBOE IPMJTUJDUSFBUNFOU t$SFBUFPQQPSUVOJUJFTUPTIBSFJOGPSNBUJPOBDSPTT HFPHSBQIJDBMEFNPHSBQIJDT t&ODPVSBHFDPMMBCPSBUJPOCFUXFFOTVCTQFDJBMJUJFT t1SPNPUFQBSUOFSTIJQBNPOHQIZTJDJBOTBOE IFBMUIQSPGFTTJPOBMT Visit ACRannualmeeting.orgGPSTVCNJTTJPOEFUBJMT %FBEMJOFGPSTVCNJTTJPOTJT Friday, November 21, 2014 session 3 tracker hƐĞƚŚĞ^ĞƐƐŝŽŶdƌĂĐŬĞƌƚŽƌĞĐŽƌĚLJŽƵƌDͬ,ŽƵƌƐŽĨWĂƌƟĐŝƉĂƟŽŶĂƐLJŽƵŐŽ, ƚŚĞŶƵƐĞƚŚĞ^ĞƐƐŝŽŶdƌĂĐŬĞƌĂƐĂŐƵŝĚĞƚŽĂƉƉůLJĨŽƌDͬ,ŽƵƌƐŽĨWĂƌƟĐŝƉĂƟŽŶ online at ǁǁǁ͘ZĂŶŶƵĂůŵĞĞƟŶŐ͘ŽƌŐƚŽŽďƚĂŝŶĂĐĞƌƟĮĐĂƚĞĨŽƌLJŽƵƌƌĞĐŽƌĚƐ͘ &EVDBUJPOBM5SBDLT >ŽŽŬĨŽƌƚŚĞƐĞŝĐŽŶƐƚŽŶĂǀŝŐĂƚĞƚŚĞŵĞĞƟŶŐďLJƚƌĂĐŬ͗ PR I M A RY T R AC K S BASIC SCIENCE BUSINESS/ADMINISTRATION E ETHICS PM CLINICAL SCIENCE PAIN MANAGEMENT PS CLINICAL PRACTICE PATIENT SAFETY S EC O N DA RY T R AC K S PM Ed Educators FIT Fellows-In-Training ĐĐƌĞĚŝƚĂƟŽŶ^ƚĂƚĞŵĞŶƚ͗ The American College of Rheumatology is accredited by the ĐĐƌĞĚŝƚĂƟŽŶŽƵŶĐŝůĨŽƌŽŶƟŶƵŝŶŐDĞĚŝĐĂů ĚƵĐĂƟŽŶ;DͿƚŽƉƌŽǀŝĚĞĐŽŶƟŶƵŝŶŐ ŵĞĚŝĐĂůĞĚƵĐĂƟŽŶĨŽƌƉŚLJƐŝĐŝĂŶƐ͘ ĞƐŝŐŶĂƟŽŶ^ƚĂƚĞŵĞŶƚ͗ The ACR designates this ůŝǀĞĞĚƵĐĂƟŽŶĂůĂĐƟǀŝƚLJĨŽƌĂŵĂdžŝŵƵŵŽĨ52.25 DWZĂƚĞŐŽƌLJϭƌĞĚŝƚƐΡ͘WŚLJƐŝĐŝĂŶƐƐŚŽƵůĚ claim only the credit commensurate with the ĞdžƚĞŶƚŽĨƚŚĞŝƌƉĂƌƟĐŝƉĂƟŽŶŝŶƚŚĞĂĐƟǀŝƚLJ͘ /ŶƚĞƌŶĂƟŽŶĂůWŚLJƐŝĐŝĂŶƐ͗/ŶƚĞƌŶĂƟŽŶĂůƉŚLJƐŝĐŝĂŶƐ ǁŚŽƌĞŐŝƐƚĞƌĂƐƉĂƌƚŽĨĂŐƌŽƵƉĂŶĚƌĞƋƵŝƌĞ DWZĂƚĞŐŽƌLJϭƌĞĚŝƚ;ƐͿΡŵƵƐƚƉƌŽǀŝĚĞ ƚŚĞĨŽůůŽǁŝŶŐŝŶĨŽƌŵĂƟŽŶƚŽLJŽƵƌƚŽƵƌůĞĂĚĞƌ͗ ĨƵůůŶĂŵĞ͕ŵĂŝůŝŶŐĂĚĚƌĞƐƐ͕ƚĞůĞƉŚŽŶĞĂŶĚĨĂdž ŶƵŵďĞƌƐĂŶĚĞͲŵĂŝůĂĚĚƌĞƐƐ͘dŚĞŝŶĨŽƌŵĂƟŽŶ ǁŝůůďĞƵƐĞĚƚŽǀĞƌŝĨLJLJŽƵƌŵĞĞƟŶŐĂƩĞŶĚĂŶĐĞ͘ dŚĞŵĞƌŝĐĂŶDĞĚŝĐĂůƐƐŽĐŝĂƟŽŶŚĂƐĂŶ ĂŐƌĞĞŵĞŶƚŽĨŵƵƚƵĂůƌĞĐŽŐŶŝƟŽŶŽĨĐŽŶƟŶƵŝŶŐ ŵĞĚŝĐĂůĞĚƵĐĂƟŽŶĐƌĞĚŝƚǁŝƚŚƚŚĞƵƌŽƉĞĂŶ hŶŝŽŶŽĨDĞĚŝĐĂů^ƉĞĐŝĂůƟĞƐ͘/ŶƚĞƌŶĂƟŽŶĂů ƉŚLJƐŝĐŝĂŶƐŝŶƚĞƌĞƐƚĞĚŝŶĐŽŶǀĞƌƟŶŐAMA PRA ĂƚĞŐŽƌLJϭƌĞĚŝƚΡƚŽDĐƌĞĚŝƚƐŚŽƵůĚ ĐŽŶƚĂĐƚƚŚĞhD^͘ Pd PS Pediatrics Practice Management ,ĞĂůƚŚWƌŽĨĞƐƐŝŽŶĂůƐ͗WĂƌƟĐŝƉĂŶƚƐŵĂLJĐůĂŝŵ ŚŽƵƌƐƚŽƌĞĐĞŝǀĞĂĞƌƟĮĐĂƚĞŽĨWĂƌƟĐŝƉĂƟŽŶĨŽƌ ĂŶĂĐƟǀŝƚLJĚĞƐŝŐŶĂƚĞĚĨŽƌDWZĂƚĞŐŽƌLJϭ ƌĞĚŝƚ;ƐͿΡ͘&ŽƌŶŽŶͲDƐĞƐƐŝŽŶƐ͕ĂƩĞŶĚĞĞƐŵĂLJ ĂůƐŽƌĞƋƵĞƐƚĂĐĞƌƟĮĐĂƚĞŽĨƉĂƌƟĐŝƉĂƟŽŶ͘ $-"*.*/($.&$3&%*5 zŽƵŵĂLJĐůĂŝŵLJŽƵƌDĐƌĞĚŝƚĂƚƚŚĞdĞĐŚŶŽůŽŐLJ ĞŶƚĞƌ͕ůŽĐĂƚĞĚŽŶ>ĞǀĞůϭŝŶƚŚĞEŽƌƚŚ>ŽďďLJ͕ ĚƵƌŝŶŐŽƌĂƚƚŚĞĞŶĚŽĨƚŚĞŵĞĞƟŶŐĨŽƌĂůů ƐĞƐƐŝŽŶƐĂƩĞŶĚĞĚ͘zŽƵŵĂLJĂůƐŽĐůĂŝŵLJŽƵƌ ĐƌĞĚŝƚŽŶůŝŶĞĚƵƌŝŶŐĂŶĚĂŌĞƌƚŚĞŵĞĞƟŶŐĂƚ ZĂŶŶƵĂůŵĞĞŐƟŶŐ͘ŽƌŐ͘ How Do I Claim Credit?/ƚŝƐĂŶDƌĞƋƵŝƌĞŵĞŶƚ ƚŚĂƚLJŽƵĐůĂŝŵŽŶůLJƚŚĞydĂŵŽƵŶƚŽĨƟŵĞ ƐƉĞŶƚŝŶĞĂĐŚĞĚƵĐĂƟŽŶĂůƐĞƐƐŝŽŶ͘dŚŝƐĂĐĐƵƌĂƚĞůLJ ƌĞŇĞĐƚƐƚŚĞĞdžƚĞŶƚŽĨLJŽƵƌƉĂƌƟĐŝƉĂƟŽŶŝŶƚŚĞ ĂĐƟǀŝƚLJ͘zŽƵŵĂLJĂƩĞŶĚƐĞƐƐŝŽŶƐĨŽƌ>^^ƚŚĂŶ ƚŚĞŝƌĞŶƟƌĞƚLJĂŶĚĐůĂŝŵƉĂƌƟĂůĐƌĞĚŝƚƚŽƚŚĞ ŶĞĂƌĞƐƚƋƵĂƌƚĞƌŚŽƵƌ͘EŽƚĞƚŚĂƚLJŽƵŵĂLJEKd ĐůĂŝŵĐƌĞĚŝƚŚŽƵƌƐĨŽƌĂƩĞŶĚŝŶŐƚǁŽĨƵůůƐĞƐƐŝŽŶƐ ĂƚĂŐŝǀĞŶƟŵĞŝŶƚŚĞŝƌĞŶƟƌĞƚLJ͘dŚĞƌĞĨŽƌĞ͕ŝĨLJŽƵ ŝŶĂĐĐƵƌĂƚĞůLJƌĞĐŽƌĚLJŽƵƌĐƌĞĚŝƚŚŽƵƌƐĂŶĚĞdžĐĞĞĚ ƚŚĞŵĞĞƟŶŐŵĂdžŝŵƵŵŽĨDͬWZĂƚĞŐŽƌLJϭ ƌĞĚŝƚƐ™, you will need to correct your claim in ŽƌĚĞƌƚŽƌĞĐĞŝǀĞLJŽƵƌĐĞƌƟĮĐĂƚĞ͘ 4 2014 ACR /A R H P A n n u a l M e e t i n g Example͗zŽƵĂƩĞŶĚŚĂůĨŽĨĂϭͲŚŽƵƌƐĞƐƐŝŽŶĂŶĚ ŚĂůĨŽĨĂŶŽƚŚĞƌŝŶƚŚĞƐĂŵĞƟŵĞƐůŽƚ͘zŽƵmust ƌĞƉŽƌƚƚŚĂƚLJŽƵƐƉĞŶƚ͘ϱŚŽƵƌƐŝŶƚŚĞĮƌƐƚƐĞƐƐŝŽŶ ĂŶĚ͘ϱŝŶƚŚĞƐĞĐŽŶĚƐĞƐƐŝŽŶ͘/ĨLJŽƵĂƩĞŵƉƚƚŽ ĐůĂŝŵĨƵůůĐƌĞĚŝƚ;ϭŚƌͿĨŽƌĞĂĐŚŽĨƚŚĞƚǁŽƐĞƐƐŝŽŶƐ͕ ƚŚĞĐůĂŝŵƐLJƐƚĞŵŵĂLJŽǀĞƌͲĐĂůĐƵůĂƚĞLJŽƵƌD ĐƌĞĚŝƚĂŶĚLJŽƵŵĂLJĞdžĐĞĞĚƚŚĞŵĂdžŝŵƵŵŶƵŵďĞƌ ŽĨĐƌĞĚŝƚŚŽƵƌƐĂůůŽǁĞĚ͘/ŶƚŚŝƐĐĂƐĞLJŽƵǁŽƵůĚŶŽƚ ďĞĂďůĞƚŽƌĞĐĞŝǀĞLJŽƵƌĐĞƌƟĮĐĂƚĞ͘ How Do I Claim Credit for Poster Sessions? You ŵĂLJŽŶůLJďĞĂǁĂƌĚĞĚDĐƌĞĚŝƚĨŽƌǀŝĞǁŝŶŐ ƉŽƐƚĞƌƐĚƵƌŝŶŐƚŚĞϵ͗ϬϬʹϭϭ͗ϬϬÃƟŵĞƐůŽƚ͘/ƚ ŝƐĂŶDƌĞƋƵŝƌĞŵĞŶƚƚŚĂƚƉŽƐƚĞƌƉƌĞƐĞŶƚĞƌƐ ŵƵƐƚďĞĂǀĂŝůĂďůĞƚŽĞŶŐĂŐĞůĞĂƌŶĞƌƐ͘zŽƵŵƵƐƚ ƚŚĞƌĞĨŽƌĞĐůĂŝŵKE>zƚŚĞĐƌĞĚŝƚĐŽŵŵĞŶƐƵƌĂƚĞ ǁŝƚŚƚŚĞĞdžƚĞŶƚĨŽƌLJŽƵƌƉĂƌƟĐŝƉĂƟŽŶŝŶƚŚĞ ĂĐƟǀŝƚLJĚƵƌŝŶŐƚŚŝƐƟŵĞƐůŽƚ͘zŽƵŵĂLJĐůĂŝŵ ƉĂƌƟĂůĐƌĞĚŝƚ͘ IMPORTANT LOCATIONS ZKĸĐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘260; dĞůĞƉŚŽŶĞ͗;ϲϭϳͿϵϱϰͲϯϵϰϬ ƩĞŶĚĞĞ>ŽƵŶŐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘Ballroom Lobby Business Center͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘>ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ ĂƌĞĞƌŽŶŶĞĐƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ,Ăůů͗ŝƐĐŽǀĞƌLJĞŶƚĞƌ ;ŽŽƚŚηϳϯϭͿ Child Care͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ĂůůĨŽƌ>ŽĐĂƟŽŶ͖dĞůĞƉŚŽŶĞ͗ ;ϲϭϳͿϵϱϰͲϯϰϱϭ ŽĂƚͬĂŐŐĂŐĞŚĞĐŬ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘>ĞǀĞůϭ͗EŽƌƚŚĞĂƐƚ>ŽďďLJ;ŶĞĂƌϭϱϲͿ ŽŶĐŝĞƌŐĞĞŶƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘>ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ Discovery Center͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ,Ăůů;ŽŽƚŚηϳϯϭͿ Exhibit Hall͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ,Ăůů First Aid ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘>ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ &ŽƵŶĚĂƟŽŶŽŽƚŚ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ,Ăůů͗ŝƐĐŽǀĞƌLJĞŶƚĞƌ ;ŽŽƚŚηϳϯϭͿ &ŽƵŶĚĂƟŽŶŽŶŽƌƐ͛>ŽƵŶŐĞ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ŽĂƌĚƌŽŽŵ;^ƵŝƚĞϮϬϭͿ ,ŽƚĞůZĞƐĞƌǀĂƟŽŶƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ>ĞǀĞů͗ZĞŐŝƐƚƌĂƟŽŶ /ŶĚƵƐƚƌLJͲ^ƵƉƉŽƌƚĞĚ^LJŵƉŽƐŝĂ/ŶĨŽƌŵĂƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘>ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘džŚŝďŝƚ,Ăůů;ŽŽƚŚƐηϭϯϵĂŶĚηϭϰϬϭͿ >ŽƐƚĂŶĚ&ŽƵŶĚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ZKĸĐĞ;ϮϲϬͿ DĞŵďĞƌƐŚŝƉŽŽƚŚ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ>ĞǀĞů͗ZĞŐŝƐƚƌĂƟŽŶ Newsroom͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ϮϱϮ͖dĞůĞƉŚŽŶĞ͗;ϲϭϳͿϵϱϰͲϯϵϰϯ EƵƌƐŝŶŐDŽƚŚĞƌƐ͛ZŽŽŵ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ϭϲϮͲ KǀĞƌŇŽǁZŽŽŵƐ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ϭϬϵ͕ϮϬϰĂŶĚϮϱϵ Poster Hall͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘džŚŝďŝƚ,Ăůů Prayer Room ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ϭϬϲ ZĞĐŚĂƌŐĞƌĞĂƐ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ƩĞŶĚĞĞ>ŽƵŶŐĞ͕dĞĐŚŶŽůŽŐLJĞŶƚĞƌ ĂŶĚtŝͲ&ŝtĂLJ session tracker ZĞŐŝƐƚƌĂƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ>ĞǀĞů͗ĂƐƚZĞŐŝƐƚƌĂƟŽŶ ZĞƐƚĂƵƌĂŶƚZĞƐĞƌǀĂƟŽŶƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ ZŝďďŽŶŝƐƚƌŝďƵƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ>ĞǀĞů͗ZĞŐŝƐƚƌĂƟŽŶ ^ŚƵƩůĞƵƐ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ >ĞǀĞůϭ;ŶĞĂƌϭϱϲͿ ^ŝŵƉůĞdĂƐŬƐ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů͗ŝƐĐŽǀĞƌLJĞŶƚĞƌ ;ŽŽƚŚηϳϯϭͿ ^ƉĞĂŬĞƌZĞĂĚLJZŽŽŵ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ 206 dĞĐŚŶŽůŽŐLJĞŶƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ >ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ sŝƐŝƚŽƌ/ŶĨŽƌŵĂƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ >ĞǀĞůϭ͗EŽƌƚŚ>ŽďďLJ Wheelchairs͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ KƌĚĞƌƚŚƌŽƵŐŚ^ĐŽŽƚƌŽƵŶĚ͕/ŶĐ͖͘ dĞůĞƉŚŽŶĞ͗;ϴϴϴͿϰϰϭ͘ϳϱϳϱ tŝͲ&ŝtĂLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ^ƉĞĐŝĂůEĞĞĚƐ /ĨLJŽƵƌĞƋƵŝƌĞƐƉĞĐŝĂůĂƌƌĂŶŐĞŵĞŶƚƐ͕ƉůĞĂƐĞĐŽŶƚĂĐƚƚŚĞZKĸĐĞ;ZŽŽŵϮϲϬͿ͖ dĞůĞƉŚŽŶĞ͗ ;ϲϭϳͿϵϱϰͲϯϵϰϬ͘ ŵĞƌŐĞŶĐLJŽŶƚĂĐƚ/ŶĨŽƌŵĂƟŽŶ ^ƉĂĐĞŝƐƉƌŽǀŝĚĞĚŽŶƚŚĞďĂĐŬŽĨLJŽƵƌďĂĚŐĞƚŽůŝƐƚŶĂŵĞĂŶĚƚĞůĞƉŚŽŶĞŶƵŵďĞƌƐŽĨ LJŽƵƌĞŵĞƌŐĞŶĐLJĐŽŶƚĂĐƚƐ͘WůĞĂƐĞĐŽŵƉůĞƚĞƚŚŝƐŝŶĨŽƌŵĂƟŽŶďĞĨŽƌĞŝŶƐĞƌƟŶŐLJŽƵƌďĂĚŐĞ ŝŶLJŽƵƌďĂĚŐĞŚŽůĚĞƌ͘ #PTUPO$POWFOUJPO BOE&YIJCJUJPO$FOUFS ΎůůŝŵƉŽƌƚĂŶƚůŽĐĂƟŽŶƐĂƌĞůŽĐĂƚĞĚŝŶƚŚĞŽƐƚŽŶŽŶǀĞŶƟŽŶĂŶĚdžŚŝďŝƟŽŶĞŶƚĞƌ͘ WƌŝŶƟŶŐŽĨƚŚŝƐƉƵďůŝĐĂƟŽŶŝƐƐƵƉƉŽƌƚĞĚďLJŵŐĞŶ͕/ŶĐ͘ 5 6 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance FRIDAY & SATURDAY, NOVEMBER 14 – 15, 2014 FRIDAY, NOVEMBER 14, 2014 Location Time Title ϲ͗ϯϬÃʹ ϲ͗ϬϬÖà ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ džŚŝďŝƚ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ ZĞŐŝƐƚƌĂƟŽŶͿ CME/Hours of Participation WZ͵Dd/E'KhZ^^ ϳ͗ϰϱÃʹ ϱ͗ϯϬÖà ACR Musculoskeletal Ultrasound Course for ZŚĞƵŵĂƚŽůŽŐŝƐƚƐʹĂLJKŶĞŽĨdǁŽ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ ϵ͗ϬϬÃʹ ϱ͗ϬϬÖà ZĚǀĂŶĐĞĚZŚĞƵŵĂƚŽůŽŐLJŽĚŝŶŐŽƵƌƐĞ͗ĞǀĞůŽƉŝŶŐ džƉĞƌƚƐŝŶZŚĞƵŵĂƚŽůŽŐLJŽĚŝŶŐĂŶĚ/ͲϭϬͲD ͘ ͘ ͘ ͘ Ϯϱϳ ϭ͗ϬϬÖÃʹ ϲ͗ϬϬÖà ZĂƐŝĐZĞƐĞĂƌĐŚŽŶĨĞƌĞŶĐĞ͗ŵĞƌŐŝŶŐWĞƌƐƉĞĐƟǀĞƐ ŽŶƚŚĞDŝĐƌŽďŝŽŵĞŝŶƚŚĞZŚĞƵŵĂƟĐŝƐĞĂƐĞƐʹĂLJKŶĞ of Two ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ ϰ͘ϳϱŚƌƐ͘ ϭ͗ϬϬÖÃʹ ϲ͗ϬϬÖà ZůŝŶŝĐĂůZĞƐĞĂƌĐŚŽŶĨĞƌĞŶĐĞ͗WĂƟĞŶƚͲĞŶƚĞƌĞĚ KƵƚĐŽŵĞƐŝŶZŚĞƵŵĂƚŽůŽŐLJʹĂLJKŶĞŽĨdǁŽ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ ϰ͘ϱŚƌƐ͘ ϭ͗ϬϬÖÃʹ ϲ͗ϭϬÖà Zͬ/DDĂŝŶƚĞŶĂŶĐĞŽĨĞƌƟĮĐĂƟŽŶ>ĞĂƌŶŝŶŐ^ĞƐƐŝŽŶʹ ϮϬϭϰhƉĚĂƚĞŝŶZŚĞƵŵĂƚŽůŽŐLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϴ ϰ͘ϳϱŚƌƐ͘ ϴ͘ϮϱŚƌƐ͘ SATURDAY, NOVEMBER 15, 2014 Location Time Title ϲ͗ϯϬÃʹ ϲ͗ϯϬÖà ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ džŚŝďŝƚ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ ZĞŐŝƐƚƌĂƟŽŶͿ CME/Hours of Participation WZ͵Dd/E'KhZ^^ ϳ͗ϭϱÃʹ ϱ͗ϱϬÖà ACR Musculoskeletal Ultrasound Course for ZŚĞƵŵĂƚŽůŽŐŝƐƚƐʹĂLJdǁŽŽĨdǁŽ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ ϵ͘ϬϬŚƌƐ͘ ϳ͗ϰϱÃʹ ϰ͗ϯϬÖà ZůŝŶŝĐĂůZĞƐĞĂƌĐŚŽŶĨĞƌĞŶĐĞ͗WĂƟĞŶƚͲĞŶƚĞƌĞĚ KƵƚĐŽŵĞƐŝŶZŚĞƵŵĂƚŽůŽŐLJʹĂLJdǁŽŽĨdǁŽ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ ϳ͘ϳϱŚƌƐ͘ ϴ͗ϬϬÃʹ ϰ͗ϬϬÖà ZWƌĂĐƟĐĞDĂŶĂŐĞŵĞŶƚWƌĞͲŵĞĞƟŶŐŽƵƌƐĞ ͘ ͘ ͘ ͘ Ϯϱϳ ϳ͘ϬŚƌƐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 7 tracker SATURDAY & SUNDAY, NOVEMBER 15 – 16, 2014 Meeting At-A-Glance Location CME/Hours Time Title ϴ͗ϬϬÃʹ ϰ͗ϬϬÖà ACR Review Course ϴ͗ϬϬÃʹ ϰ͗ϯϬÖà ZĂƐŝĐZĞƐĞĂƌĐŚŽŶĨĞƌĞŶĐĞ͗ŵĞƌŐŝŶŐWĞƌƐƉĞĐƟǀĞƐ ŽŶƚŚĞDŝĐƌŽďŝŽŵĞŝŶƚŚĞZŚĞƵŵĂƟĐŝƐĞĂƐĞƐʹĂLJdǁŽŽĨ Two ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ ϲ͘ϮϱŚƌƐ͘ ϴ͗ϬϬÃʹ ϰ͗ϯϬÖà Z,WůŝŶŝĐĂů&ŽĐƵƐŽƵƌƐĞ͗ŝĂŐŶŽƐƟĐ/ŵĂŐŝŶŐhƐĞ ŝŶŝīĞƌĞŶƟĂůŝĂŐŶŽƐŝƐĨŽƌŽŵŵŽŶZŚĞƵŵĂƟĐĂŶĚ DƵƐĐƵůŽƐŬĞůĞƚĂůŽŶĚŝƟŽŶƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ ϳ͘ϬŚƌƐ͘ ϵ͗ϬϬÃʹ ϰ͗ϬϬÖà DDĞĚŝĐĂůĚƵĐĂƟŽŶZĞƐĞĂƌĐŚĞƌƟĮĐĂƚĞ;DZͿ tŽƌŬƐŚŽƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϰ of Participation ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϲ͘ϬŚƌƐ͘ SCIENTIFIC SESSIONS ϰ͗ϯϬÖÃʹ ϲ͗ϭϱÖà ZͬZ,WKƉĞŶŝŶŐ>ĞĐƚƵƌĞĂŶĚǁĂƌĚƐ KƉĞŶŝŶŐ>ĞĐƚƵƌĞ͗WϰDĞĚŝĐŝŶĞ/ƐdƌĂŶƐĨŽƌŵŝŶŐ,ĞĂůƚŚĂƌĞ͗ >ŽŶŐŝƚƵĚŝŶĂů͕&ƌĂŵŝŶŐŚĂŵͲůŝŬĞ^ƚƵĚLJŽĨϭϬϬ͕ϬϬϬtĞůůWĂƟĞŶƚƐ KǀĞƌϮϬͲϮϱzĞĂƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϲ͗ϭϱÖÃʹ ϴ͗ϬϬÖà EĞƚǁŽƌŬŝŶŐǀĞŶƚ ZͬZ,WKƉĞŶŝŶŐZĞĐĞƉƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East and West Ϭ͘ϳϱŚƌƐ͘ SUNDAY, NOVEMBER 16, 2014 Location CME/Hours Time Title ϲ͗ϯϬÃʹ ϲ͗ϬϬÖà ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ džŚŝďŝƚ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ ZĞŐŝƐƚƌĂƟŽŶͿ ϳ͗ϯϬÃʹ ϴ͗ϯϬà ACR Sessions ϭ͘ϬŚƌ͘ ŐĞĞĨŽƌĞĞĂƵƚLJ͗ŽůĐŚŝĐŝŶĞ͕ƐƉŝƌŝŶ͕DĞƚŚŽƚƌĞdžĂƚĞĂŶĚ dŚĞŝƌDĞĐŚĂŶŝƐŵƐŽĨĐƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϯ WĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJdŽǁŶ,Ăůů ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ zĞĂƌŝŶZĞǀŝĞǁ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϳ͗ϯϬÃʹ ϴ͗ϯϬà EĞƚǁŽƌŬŝŶŐǀĞŶƚ ZͬZ,W&ŝƌƐƚͲƟŵĞƩĞŶĚĞĞKƌŝĞŶƚĂƟŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ of Participation 8 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance SUNDAY, NOVEMBER 16, 2014 Location Time Title ϳ͗ϰϱÃʹ ϵ͗ϭϱà ACR Meet the Professor Sessions ĂƐŝĐ/ŵŵƵŶŽůŽŐLJĨŽƌůŝŶŝĐĂůZŚĞƵŵĂƚŽůŽŐŝƐƚƐ;ϬϬϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ƌLJƐƚĂů͗ŝĂŐŶŽƐŝƐĂŶĚDĂŶĂŐĞŵĞŶƚŽĨ'ŽƵƚ;ϬϬϮͿ PM ͘ ͘ ͘ ͘ ͘ ͘ ƵƚĂŶĞŽƵƐsĂƐĐƵůŝƟƐ;ϬϬϯͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ &ŝďƌŽŵLJĂůŐŝĂϮϬϭϰ͗hƉĚĂƚĞŽŶDĂŶĂŐĞŵĞŶƚ;ϬϬϰͿ PM ͘ ͘ ͘ ͘ ͘ ͘ DĂĐƌŽƉŚĂŐĞĐƟǀĂƟŽŶ^LJŶĚƌŽŵĞ;ϬϬϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WĂŝŶ͗ǀĂůƵĂƟŽŶĂŶĚdƌĞĂƚŵĞŶƚŽĨĂĐŬWĂŝŶ;ϬϬϲͿ PM ͘ ͘ ͘ ͘ ͘ ͘ WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ;ϬϬϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ZĞĂĐƟǀĞƌƚŚƌŝƟƐ͗ŶhƉĚĂƚĞ;ϬϬϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŚĂůůĞŶŐŝŶŐĂƐĞƐ;ϬϬϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ŝĸĐƵůƚƚŽdƌĞĂƚ^LJƐƚĞŵŝĐ >ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ;ϬϭϬͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WĂŝŶĞ ;>ŽďďLJͿ KƟƐ ;>ŽďďLJͿ ,ĂŶĐŽĐŬ ;>ŽďďLJͿ ZĞǀĞƌĞ ;>ŽďďLJͿ ^ƚŽŶĞ ;>ŽďďLJͿ Webster ;>ŽďďLJͿ Adams ;DĞnjnjĂŶŝŶĞͿ ůĐŽƩ ;DĞnjnjĂŶŝŶĞͿ ŽƵŐůĂƐ ;DĞnjnjĂŶŝŶĞͿ CME/Hours of Participation ϭ͘ϱŚƌƐ͘ &ĂŶĞƵŝů ;DĞnjnjĂŶŝŶĞͿ ϳ͗ϰϱÃʹ ϵ͗ϰϱà ZtŽƌŬƐŚŽƉƐ :ŽŝŶƚ/ŶũĞĐƟŽŶdĞĐŚŶŝƋƵĞƐ;ϮϬϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ EĂŝůĨŽůĚĂƉŝůůĂƌŽƐĐŽƉLJ;ϮϬϮͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϭ dĂŝŚŝŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞ;ϮϬϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϰ Ϯ͘ϬŚƌƐ͘ ϴ͗ϯϬÃʹ ϭϬ͗ϬϬà ACR Sessions Z͗DĂŝŶƚĞŶĂŶĐĞŽĨĞƌƟĮĐĂƟŽŶ^ĞƐƐŝŽŶKŶĞ ŽĨdŚƌĞĞʹsĂƐĐƵůŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ƵƌƌĞŶƚhŶĚĞƌƐƚĂŶĚŝŶŐŽĨDĂůŝŐŶĂŶĐŝĞƐŝŶŽŶŶĞĐƟǀĞ dŝƐƐƵĞŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ E PM Ed Ethics and Rheumatology /ŶĨŽƌŵĂƟǀĞĂŶĚƌŝƟĐĂůWĞĞƌZĞǀŝĞǁĨŽƌƚŚĞZ:ŽƵƌŶĂůƐ͗ 'ƵŝĚĞƚŽWƌŽǀŝĚŝŶŐdžĐĞůůĞŶƚWĞĞƌZĞǀŝĞǁŽĨ FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ DĂŶƵƐĐƌŝƉƚƐ KƐƚĞŽƉŽƌŽƐŝƐ͗ƵƌƌĞŶƚŽŶĐĞƉƚƐĨŽƌƚŚĞůŝŶŝĐŝĂŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WƌĂĐƟĐĞ/ƐƐƵĞƐ͗,ĞĂůƚŚĂƌĞŽƵŶƚLJ,ƵŶƚĞƌƐ͗ůŽƐĞƌ >ŽŽŬĂƚZƐ͕ƵĚŝƚƐĂŶĚDĞĚŝĐĂůŽĐƵŵĞŶƚĂƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ dŚĞDŝĐƌŽďŝŽŵĞŝŶ,ĞĂůƚŚĂŶĚŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ tŚĞŶWŝůůƐƌĞEŽƚŶŽƵŐŚ͗DƵůƟĚŝƐĐŝƉůŝŶĂƌLJƉƉƌŽĂĐŚĞƐƚŽ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ PM WĞĚŝĂƌŝĐWĂŝŶĂŶĚ,LJƉĞƌŵŽďŝůŝƚLJ ϭ͘ϱŚƌƐ͘ ϱϮ Ballroom East Ϯϱϰ Ϯϱϳ džŚŝďŝƚ,Ăůů ϭϲϬ Ϯϱϴ ϭϬϰ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 9 tracker SUNDAY, NOVEMBER 16, 2014 Meeting At-A-Glance Location Time Title ϴ͗ϯϬÃʹ ϰ͗ϬϬÖà ACR Poster Session A and Poster Tours ďƐƚƌĂĐƚƐ;ηϭͲϴϭϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WŽƐƚĞƌ,Ăůů WŽƐƚĞƌ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϴ͗ϯϬʹϭϬ͗ϬϬÃͿ CME/Hours of Participation Ϯ͘ϬŚƌƐ͘ ;džŚŝďŝƚ,ĂůůͿ Poster Presenters Available ϵ͗ϬϬʹϭϭ͗ϬϬà Guided Poster Tours ϵ͗ϬϬʹϵ͗ϰϱà ϯϬϭʹ&ĞůůŽǁƐKŶůLJ͗,ŽǁƚŽEĂǀŝŐĂƚĞƚŚĞWŽƐƚĞƌ,Ăůů ϯϬϮʹWĂŝŶ͗ĂƐŝĐĂŶĚůŝŶŝĐĂůƐƉĞĐƚƐ ϯϬϯʹWĂƐƚWƌĞƐŝĚĞŶƚ͛ƐWŝĐŬƐWŽƐƚĞƌdŽƵƌ ϯϬϰʹWĂƐƚWƌĞƐŝĚĞŶƚ͛ƐWŝĐŬƐWŽƐƚĞƌdŽƵƌ ϯϬϱʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐdƌĞĂƚŵĞŶƚʹ^ŵĂůůDŽůĞĐƵůĞƐ͕ ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJWŽƐƚĞƌdŽƵƌ ϯϬϲʹ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐ WŽƐƚĞƌdŽƵƌ ϭϬ͗ϭϱʹϭϭ͗ϬϬà ϯϬϳʹŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞWŽƐƚĞƌdŽƵƌ ϯϬϴʹDĞƚĂďŽůŝĐĂŶĚƌLJƐƚĂůƌƚŚƌŽƉĂƚŚŝĐƐWŽƐƚĞƌdŽƵƌ ϯϬϵʹWĂƐƚWƌĞƐŝĚĞŶƚ͛ƐWŝĐŬƐWŽƐƚĞƌdŽƵƌ ϯϭϬʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ ϯϭϭʹ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐ WŽƐƚĞƌdŽƵƌ ϯϭϮʹsĂƐĐƵůŝƟƐWŽƐƚĞƌdŽƵƌ ϵ͗ϬϬÃʹ ϭϬ͗ϬϬà ACR Sessions Z/ŵŵƵŶŽůŽŐLJhƉĚĂƚĞ͗EĞǁ/ŵŵƵŶŽůŽŐLJŽĨƚŚĞ ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ ĚǀŽĐĂĐLJ͗DĞĞƚƚŚĞdžƉĞƌƚʹ^ĞŶĂƚŽƌ͛ƐWĞƌƐƉĞĐƟǀĞ ŽŶĚǀŽĐĂĐLJĞƐƚWƌĂĐƟĐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ ^ĂƌĐŽŝĚŽƐŝƐŝŶϮϬϭϰ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom West ^ŽĐŝĂůDĞĚŝĂŽŽƚĂŵƉ͗dǁŝƩĞƌĂƐŝĐƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ ϭ͘ϬŚƌ͘ ϵ͗ϬϬÃʹ ϭϬ͗ϬϬà ARHP Session Z,W<ĞLJŶŽƚĞĚĚƌĞƐƐ͗,ĂƉƉŝŶĞƐƐ&ƌŽŵƚŚĞ/ŶƐŝĚĞKƵƚ ϭ͘ϬŚƌ͘ ͘ ͘ ϭϬϳ ϭϬ͗ϬϬÃʹ Exhibits ϱ͗ϬϬÖà džŚŝďŝƚ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϭϬ͗ϬϬʹϭϭ͗ϬϬÃͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů džŚŝďŝƚ,ĂůůŌĞƌŶŽŽŶ^ŶĂĐŬƌĞĂŬ;Ϯ͗ϬϬʹϯ͗ϬϬÖÃͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ 10 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance Time SUNDAY, NOVEMBER 16, 2014 Location Title CME/Hours of Participation ϭϬ͗ϯϬÃʹ Exhibits ϭϭ͗ϭϱà /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϯϵͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ ϭϬ͗ϯϬÃʹ ZtŽƌŬƐŚŽƉƐ ϭϮ͗ϯϬÖà ĞLJŽŶĚDƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚĨŽƌZŚĞƵŵĂƚŽůŽŐŝƐƚƐ ;ϮϬϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ůŝŶŝĐĂůŶĂƚŽŵLJĂŶĚWŚLJƐŝĐĂůdžĂŵ͗ƐƐĞŶƟĂůdŽŽůƐŝŶhƉƉĞƌ džƚƌĞŵŝƚLJZĞŐŝŽŶĂůWĂŝŶ^LJŶĚƌŽŵĞƐ;ϮϬϱͿ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ,ŝƐƚŽƉĂƚŚŽůŽŐLJŽĨZŚĞƵŵĂƟĐ>ƵŶŐŝƐĞĂƐĞ;ϮϬϲͿ͘͘͘͘͘͘͘͘͘͘͘ ^LJŶŽǀŝĂů&ůƵŝĚŶĂůLJƐŝƐĂŶĚƌLJƐƚĂů/ĚĞŶƟĮĐĂƟŽŶ;ϮϬϳͿ͘ ͘ ͘ ͘ ͘ ͘ Ϯ͘ϬŚƌƐ͘ ϭϱϵ ϭϱϮ ϭϱϰ ϭϲϭ ϭϭ͗ϬϬÃʹ ACR Sessions EŽŽŶ Bone Biology ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ EĞǁZZĞĐŽŵŵĞŶĚĂƟŽŶƐĨŽƌƚŚĞDĂŶĂŐĞŵĞŶƚŽĨ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East PM ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ ϭ͘ϬŚƌ͘ ϭϭ͗ϬϬÃʹ ARHP Sessions EŽŽŶ īŽƌĚĂďůĞĂƌĞĐƚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ /ŵŵƵŶŽůŽŐLJŽŽƚĂŵƉ/͗dŚĞĂƐŝĐƐŽĨdĂƌŐĞƚĞĚ dŚĞƌĂƉŝĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ tŚĂƚĂŶƌĂŝŶ/ŵĂŐŝŶŐdĞůůhƐďŽƵƚWŚĂƌŵĂĐŽůŽŐŝĐĂŶĚ PM ͘ ͘ ͘ ͘ ͘ Ϯϱϰ EŽŶͲWŚĂƌŵĂĐŽůŽŐŝĐdƌĞĂƚŵĞŶƚŽĨŚƌŽŶŝĐWĂŝŶ͍ ϭ͘ϬŚƌ͘ ϭϭ͗ϬϬÃʹ ZWůĞŶĂƌLJ^ĞƐƐŝŽŶ/͗ŝƐĐŽǀĞƌLJϮϬϭϰ ϭϮ͗ϯϬÖà ďƐƚƌĂĐƚƐ;ηϴϭϱͲϴϭϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϭ͘ϱŚƌƐ͘ ϭϭ͗ϯϬÃʹ Exhibits ϭϮ͗ϭϱÖà /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϰϬϭͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ ϭϮ͗ϯϬÖÃʹ Exhibits ϭ͗ϭϱÖà /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϯϵͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ ϭϮ͗ϯϬÖÃʹ EĞƚǁŽƌŬŝŶŐǀĞŶƚ Ϯ͗ϭϱÖà Z,WEĞƚǁŽƌŬŝŶŐ&ŽƌƵŵ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϮ͗ϰϱÖÃʹ ACR Session Ϯ͗ϭϱÖà Z<ŶŽǁůĞĚŐĞŽǁů͗WƌĞůŝŵŝŶĂƌLJZŽƵŶĚ Commonwealth Ballroom ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom West ϭ͘ϱŚƌƐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 11 tracker SUNDAY, NOVEMBER 16, 2014 Time Meeting At-A-Glance Title Location ϭϮ͗ϰϱÖÃʹ ACR Meet the Professor Sessions Ϯ͗ϭϱÖà ŶŬLJůŽƐŝŶŐ^ƉŽŶĚLJůŝƟƐ͗ϮϬϭϰhƉĚĂƚĞ;ϬϭϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WĂŝŶĞ ;>ŽďďLJͿ KƟƐ ŶŬLJůŽƐŝŶŐ^ƉŽŶĚLJůŝƟƐ͗ŝƐĞĂƐĞDŽĚŝĮĐĂƟŽŶ;ϬϭϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;>ŽďďLJͿ ĞƌŵĂƚŽůŽŐŝĐĂůDĂŶŝĨĞƐƚĂƟŽŶƐŽĨZŚĞƵŵĂƟĐ ŝƐĞĂƐĞƐ;ϬϭϯͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ,ĞƌĞĚŝƚĂƌLJŶŐŝŽĞĚĞŵĂhƉĚĂƚĞ;ϬϭϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WĞĚŝĂƚƌŝĐ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ;ϬϭϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŝŽůŽŐŝĐĂůŐĞŶƚƐ;ϬϭϲͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗EŽǀĞůdƌĞĂƚŵĞŶƚƐ;ϬϭϳͿ͘ ͘ ͘ ͘ ͘ sĂĐĐŝŶĂƟŽŶƐĨŽƌWĂƟĞŶƚƐŽŶŝŽůŽŐŝĐdŚĞƌĂƉŝĞƐ;ϬϭϴͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ sĂƐĐƵůŝƟƐ͗hƉĚĂƚĞ;ϬϭϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ tŚĂƚ/ƐEŽƚĞŶƚƌĂůEĞƌǀŽƵƐŶŐŝŝƟƐ͗DĂŬŝŶŐƚŚĞZŝŐŚƚ ŝĂŐŶŽƐŝƐ;ϬϮϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ CME/Hours of Participation ϭ͘ϱŚƌƐ͘ ,ĂŶĐŽĐŬ ;>ŽďďLJͿ ZĞǀĞƌĞ ;>ŽďďLJͿ ^ƚŽŶĞ ;>ŽďďLJͿ Webster ;>ŽďďLJͿ Adams ;DĞnjnjĂŶŝŶĞͿ ůĐŽƩ ;DĞnjnjĂŶŝŶĞͿ ŽƵŐůĂƐ ;DĞnjnjĂŶŝŶĞͿ &ĂŶĞƵŝů ;DĞnjnjĂŶŝŶĞͿ ϭ͗ϬϬÖÃʹ Ϯ͗ϬϬÖà ACR Sessions ϭ͘ϬŚƌ͘ ǀŽŝĚŝŶŐůĞĐƚƌŽŶŝĐ,ĞĂůƚŚZĞĐŽƌĚƌƌŽƌƐĂŶĚdŚĞŝƌ ;^ŽŵĞƟŵĞƐͿƌŝƟĐĂůŽŶƐĞƋƵĞŶĐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ PM džŝĂů^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ'ƵŝĚĞůŝŶĞƐ FIT PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů 'ŽƵƚDĂŶĂŐĞŵĞŶƚŝŶϮϬϭϰ ,ŽǁƚŚĞ'ƵƚWƌŝŵĞƐƚŚĞ/ŵŵƵŶĞ^LJƐƚĞŵ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ WƌĂĐƟĐĞ/ƐƐƵĞƐ͗dŚĞZŽĂĚƚŽ/ϭϬ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ ZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶDĞŵŽƌŝĂů>ĞĐƚƵƌĞƐŚŝƉƚŽ ,ŽŶŽƌƌ͘^ƚĞƉŚĞŶ͘DĂůĂǁŝƐƚĂ͕D͗/ŶŶĂƚĞ/ŵŵƵŶŝƚLJĂƚƚŚĞ E ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ ŽƌĞŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞ dŚĞƵƩĞƌŇLJīĞĐƚ͗>ƵƉƵƐZĂƐŚĞƐĂŶĚdŚĞŝƌDŝŵŝĐƐ ͘ ͘ ͘ ͘ ͘ Ballroom East ϭ͗ϭϱÖÃʹ ϯ͗ϭϱÖà ZtŽƌŬƐŚŽƉƐ ĚǀĂŶĐĞĚDƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ;ϮϬϴͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ ůŝŶŝĐĂůŶĂƚŽŵLJĂŶĚWŚLJƐŝĐĂůdžĂŵ͗ƐƐĞŶƟĂůdŽŽůƐŝŶ >ŽǁĞƌdžƚƌĞŵŝƚLJZĞŐŝŽŶĂůWĂŝŶ^LJŶĚƌŽŵĞƐ;ϮϬϵͿ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ ϭ͗ϯϬÖÃʹ Ϯ͗ϭϱÖà Exhibits /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϰϬϭͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ Ϯ͗ϯϬÖÃʹ ϯ͗ϭϱÖà Exhibits /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϯϵͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ Ϯ͘ϬŚƌƐ͘ 12 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance SUNDAY, NOVEMBER 16, 2014 Location Time Title Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ACR Sessions ƵƚŽŝŵŵƵŶŝƚLJŝŶ/ŵŵƵŶŽĚĞĮĐŝĞŶĐLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ PM Ed ͘ ͘ ͘ ͘ ĚƵĐĂƚŽƌ͗DĞĚŝĐĂůĚƵĐĂƟŽŶ͗dŚĞzĞĂƌŝŶZĞǀŝĞǁ EĞǁ&ƌŽŶƟĞƌƐŝŶKƐƚĞŽĂƌƚŚƌŝƟƐdƌĞĂƚŵĞŶƚ͗dŚĞZŽůĞ ŽĨtĞŝŐŚƚ>ŽƐƐ͕^ƵƌŐĞƌLJĂŶĚƵƌƌĞŶƚdƌĞĂƚŵĞŶƚ FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ 'ƵŝĚĞůŝŶĞƐ dŚĞ'ƌĞĂƚĞďĂƚĞ͗ĞůŝŵƵŵĂďĨŽƌƚŚĞdƌĞĂƚŵĞŶƚŽĨ^LJƐƚĞŵŝĐ >ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ACR Concurrent Abstract Sessions ;ηϴϮϬͲϴϮϱͿƉŝĚĞŵŝŽůŽŐLJĂŶĚWƵďůŝĐ,ĞĂůƚŚ/͗ƌƵŐĂŶĚ sĂĐĐŝŶĞ^ĂĨĞƚLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϴϮϲͲϴϯϭͿDĞƚĂďŽůŝĐĂŶĚƌLJƐƚĂůƌƚŚƌŽƉĂƚŚŝĞƐ/͗ ůŝŶŝĐĂůƐƉĞĐƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϴϯϮͲϴϯϳͿDŝƐĐĞůůĂŶĞŽƵƐZŚĞƵŵĂƟĐĂŶĚ/ŶŇĂŵŵĂƚŽƌLJ ŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϴϯϴͲϴϰϯͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ/͗ ĂƌĚŝŽǀĂƐĐƵůĂƌŝƐĞĂƐĞZŝƐŬ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϴϰϰͲϴϰϵͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕ ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJ/͗^ĂĨĞƚLJŽĨŝŽůŽŐŝĐƐĂŶĚ ^ŵĂůůDŽůĞĐƵůĞƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹDĂůŝŐŶĂŶĐLJ ĂŶĚ/ŶĨĞĐƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϴϱϬͲϴϱϱͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ/ʹ EŽǀĞůdƌĞĂƚŵĞŶƚƐĨŽƌdžŝĂů^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϴϱϲͲϴϲϭͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹAnimal DŽĚĞůƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϴϲϮͲϴϲϳͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹůŝŶŝĐĂůƐƉĞĐƚƐ ĂŶĚdƌĞĂƚŵĞŶƚ͗ĂƌĚŝŽǀĂƐĐƵůĂƌŝƐĞĂƐĞĂŶĚWƌĞŐŶĂŶĐLJ ͘ ͘ ͘ ;ηϴϲϴͲϴϳϯͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹ,ƵŵĂŶƟŽůŽŐLJ ĂŶĚWĂƚŚŽŐĞŶĞƐŝƐ/͗WĂƚŚǁĂLJƐŽĨ/ŶŇĂŵŵĂƟŽŶͬ/ŶũƵƌLJ ͘ ͘ ͘ ͘ ;ηϴϳϰͲϴϳϵͿ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐĂŶĚ ZĂLJŶĂƵĚ͛ƐʹůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdŚĞƌĂƉĞƵƟĐƐ/͗^LJƐƚĞŵŝĐ ^ĐůĞƌŽƐŝƐ͕ĚǀĂŶĐĞƐŝŶdŚĞƌĂƉLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϴϴϬͲϴϴϱͿsĂƐĐƵůŝƟƐ/ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ ϭϬϮ CME/Hours of Participation ϭ͘ϱŚƌƐ͘ ϮϬϱ džŚŝďŝƚ,Ăůů ϭ͘ϱŚƌƐ͘ Ϯϱϯ ϭϬϰ ϭϲϬ Ballroom East Ballroom West ϮϭϬ ϭϱϯ Ϯϱϴ ϭϬϳ ϭϱϳ ϭϱϲ Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ARHP Sessions 'ŽŽŐůĞDŝŶĞĮĞůĚ͗ŵƉŽǁĞƌŝŶŐWĂƟĞŶƚƐƚŽǀĂůƵĂƚĞKŶůŝŶĞ FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ PM Ed Resources WƌĂĐƟĐĂůWƌĂĐƟĐĞDĂŶĂŐĞŵĞŶƚ^ĞƐƐŝŽŶKŶĞ͗/ŵƉƌŽǀĞYƵĂůŝƚLJ ĂŶĚĸĐŝĞŶĐLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ ^ƉŽƌƚƐDĞĚŝĐŝŶĞĨŽƌƚŚĞZŚĞƵŵĂƚŽůŽŐLJWƌŽǀŝĚĞƌ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ zŽƵŶŐĚƵůƚƐǁŝƚŚZŚĞƵŵĂƟĐŝƐĞĂƐĞ͗dŚĞWĂƟĞŶƚ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ WĞƌƐƉĞĐƟǀĞ ϭ͘ϱŚƌƐ͘ Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ARHP Concurrent Abstract Session ;ηϴϴϲͲϴϵϭͿdžĞŵƉůĂƌLJďƐƚƌĂĐƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ ϭ͘ϱŚƌƐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 13 tracker SUNDAY, NOVEMBER 16, 2014 Meeting At-A-Glance Location CME/Hours Time Title ϯ͗ϯϬÖÃʹ ϰ͗ϭϱÖà Exhibits /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϰϬϭͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ ϰ͗ϬϬÖÃʹ ϲ͗ϬϬÖà ZtŽƌŬƐŚŽƉƐ DĂŐŶĞƟĐZĞƐŽŶĂŶĐĞ/ŵĂŐŝŶŐŝŶƚŚĞŝĂŐŶŽƐŝƐ ĂŶĚDĂŶĂŐĞŵĞŶƚŽĨ^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ͗ůŝŶŝĐŝĂŶ͛Ɛ 'ƵŝĚĞ;ϮϭϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ DƵƐĐůĞ/ŶǀŽůǀĞŵĞŶƚŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϮϭϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϭ KƐƚĞŽƉŽƌŽƐŝƐ͗/ŶƚĞƌƉƌĞƟŶŐƵĂůŶĞƌŐLJyͲZĂLJďƐŽƌƉƟŽŵĞƚƌLJ ĂŶĚůŝŶŝĐĂůZŝƐŬ&ĂĐƚŽƌƐ͗dŚĞEĞǁ&ƌĂĐƚƵƌĞZŝƐŬƐƐĞƐƐŵĞŶƚ ůŐŽƌŝƚŚŵ;ϮϭϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϰ WŚLJƐŝĐĂůdžĂŵŝŶĂƟŽŶ^ŬŝůůƐĨŽƌ/ŵƉƌŽǀĞĚĞƚĞĐƟŽŶŽĨ ^LJŶŽǀŝƟƐĂŶĚĞƌǀŝĐĂůdŚŽƌĂĐŽůƵŵďĂƌŝƐŽƌĚĞƌƐ;ϮϭϯͿ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ Ϯ͘ϬŚƌƐ͘ ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ACR Sessions ͘ ͘ ͘ ͘ ϱϮ dŚĞƌĂƉĞƵƟĐdĂƌŐĞƟŶŐŽĨƚŚĞ/ŶŶĂƚĞ/ŵŵƵŶĞ^LJƐƚĞŵ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East dŚŝĞǀĞƐ͛DĂƌŬĞƚ͗^ŚŽǁDĞzŽƵƌĞƐƚĂƐĞƐ ϭ͘ϱŚƌƐ͘ ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ACR Concurrent Abstract Sessions ϭ͘ϱŚƌƐ͘ ;ηϴϵϮͲϴϵϳͿ&ŝďƌŽŵLJĂůŐŝĂ͕^ŽŌdŝƐƐƵĞŝƐŽƌĚĞƌƐ͕ ZĞŐŝŽŶĂůĂŶĚ^ƉĞĐŝĮĐůŝŶŝĐĂůWĂŝŶ^LJŶĚƌŽŵĞƐ/͗ZĞƐĞĂƌĐŚ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ WĞƌƐƉĞĐƟǀĞƐ ;ηϴϵϴͲϵϬϯͿ,ĞĂůƚŚ^ĞƌǀŝĐĞƐZĞƐĞĂƌĐŚ͗ZŝƐŬƐƐĞƐƐŵĞŶƚĂŶĚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ KƵƚĐŽŵĞƐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞ ;ηϵϬϰͲϵϬϵͿ/ŵĂŐŝŶŐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ͗hůƚƌĂƐŽƵŶĚ ͘ ͘ ϮϭϬ ;ηϵϭϬͲϵϭϱͿDƵƐĐůĞŝŽůŽŐLJ͕DLJŽƐŝƟƐĂŶĚDLJŽƉĂƚŚŝĞƐ ͘ ͘ ͘ ͘ ϭϲϬ ;ηϵϭϲͲϵϮϭͿKƐƚĞŽƉŽƌŽƐŝƐĂŶĚDĞƚĂďŽůŝĐŽŶĞŝƐĞĂƐĞʹ ůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚWĂƚŚŽŐĞŶĞƐŝƐ͗ůŝŶŝĐĂůKƐƚĞŽƉŽƌŽƐŝƐ͗ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ dƌĞĂƚŵĞŶƚĂŶĚ^ĂĨĞƚLJ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ ;ηϵϮϮͲϵϮϳͿWĂŝŶ͗ĂƐŝĐĂŶĚůŝŶŝĐĂůƐƉĞĐƚƐ/ ;ηϵϮϴͲϵϯϯͿWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJʹClinical and Pd PS ͘ ͘ ͘ ͘ Ϯϱϯ dŚĞƌĂƉĞƵƟĐƐƉĞĐƚƐ͗:ƵǀĞŶŝůĞ/ĚŝŽƉĂƚŚŝĐƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ϭϬϳ ;ηϵϯϰͲϵϯϵͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹŶŝŵĂůDŽĚĞůƐ/ ;ηϵϰϬͲϵϰϱͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ//͗ ZĞŵŝƐƐŝŽŶĂŶĚĞͲĞƐĐĂůĂƟŽŶŽĨdŚĞƌĂƉLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ηϵϰϲͲϵϱϭͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕ŝŽůŽŐŝĐƐ ĂŶĚ'ĞŶĞdŚĞƌĂƉLJ//͗EŽǀĞůdŚĞƌĂƉŝĞƐŝŶZŚĞƵŵĂƚŽŝĚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom ƌƚŚƌŝƟƐʹĂƌůLJŝŶĞǀĞůŽƉŵĞŶƚ ;ηϵϱϮͲϵϱϳͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ//ʹ West EŽǀĞůdƌĞĂƚŵĞŶƚƐĨŽƌWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϴ ;ηϵϱϴͲϵϲϯͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹůŝŶŝĐĂůƐƉĞĐƚƐ ĂŶĚdƌĞĂƚŵĞŶƚ͗>ƵƉƵƐEĞƉŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ ;ηϵϲϰͲϵϲϵͿ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐ ĂŶĚZĂLJŶĂƵĚ͛ƐʹWĂƚŚŽŐĞŶĞƐŝƐ͕ŶŝŵĂůDŽĚĞůƐĂŶĚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ 'ĞŶĞƟĐƐ/ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ of Participation 14 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance SUNDAY, NOVEMBER 16, 2014 Location Time Title ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ACR Meet the Professor Sessions ƌLJƐƚĂů͗ŝĂŐŶŽƐŝƐĂŶĚDĂŶĂŐĞŵĞŶƚŽĨ'ŽƵƚ;ϬϮϭͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WĂŝŶĞ ;>ŽďďLJͿ KƟƐ /ŶĨĞĐƟŽŶƐǁŝƚŚŝŽůŽŐŝĐƐ;ϬϮϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;>ŽďďLJͿ ,ĂŶĐŽĐŬ /ŶŇĂŵŵĂƚŽƌLJLJĞŝƐĞĂƐĞͬhǀĞŝƟƐ;ϬϮϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;>ŽďďLJͿ CME/Hours of Participation ϭ͘ϱŚƌƐ͘ WĞĚŝĂƚƌŝĐƐ͗ŝĸĐƵůƚƚŽdƌĞĂƚ:ƵǀĞŶŝůĞ/ĚŝŽƉĂƚŚŝĐ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ƌƚŚƌŝƟƐ;ϬϮϰͿ Pd ZĞǀĞƌĞ ;>ŽďďLJͿ ^ƚŽŶĞ WŽůLJŵLJĂůŐŝĂZŚĞƵŵĂƟĐĂ;ϬϮϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;>ŽďďLJͿ Webster WƵůŵŽŶĂƌLJ,LJƉĞƌƚĞŶƐŝŽŶŝŶƚŚĞZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϬϮϲͿ͘ ͘ ͘ ;>ŽďďLJͿ Adams ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŝŽůŽŐŝĐĂůŐĞŶƚƐ;ϬϮϳͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;DĞnjnjĂŶŝŶĞͿ ZŚĞƵŵĂƚŽůŽŐLJWƌĂĐƟĐĞϭϬϭ͗^ƚĂƌƟŶŐKƵƚŝŶWƌĂĐƟĐĞĨŽƌƚŚĞ 'ƌĂĚƵĂƟŶŐ&ĞůůŽǁ;ϬϮϴͿ FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ůĐŽƩ ;DĞnjnjĂŶŝŶĞͿ ŽƵŐůĂƐ ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗EŽǀĞůdƌĞĂƚŵĞŶƚƐ;ϬϮϵͿ͘ ͘ ͘ ͘ ;DĞnjnjĂŶŝŶĞͿ &ĂŶĞƵŝů sŝƚĂŵŝŶĂŶĚŽŶĞ,ĞĂůƚŚ;ϬϯϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;DĞnjnjĂŶŝŶĞͿ ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ACR/ARHP Combined Abstract Session ;ηϵϳϬͲϵϳϱͿZͬZ,WŽŵďŝŶĞĚďƐƚƌĂĐƚ^ĞƐƐŝŽŶ͗ ƉŝĚĞŵŝŽůŽŐLJĂŶĚWƵďůŝĐ,ĞĂůƚŚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ ϭ͘ϱŚƌƐ͘ ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ARHP Sessions ͞^ĂLJtŚĂƚ͍͗͟/ŵƉůŝĐĂƟŽŶƐŽĨĚŽůĞƐĐĞŶƚĞǀĞůŽƉŵĞŶƚ ĂŶĚĞŚĂǀŝŽƌŝŶŽŵŵƵŶŝĐĂƟŶŐtŝƚŚ,ĞĂůƚŚĂƌĞ Pd PS WƌŽǀŝĚĞƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ ƵƌƌĞŶƚdƌĞŶĚƐŝŶ^ĞůĨͲDĂŶĂŐĞŵĞŶƚĂŶĚZŚĞƵŵĂƚŽůŽŐŝĐĂƌĞ͗ ŵ,ĞĂůƚŚ͕Ğ,ĞĂůƚŚ͕ŝŐŝƚĂůdĞĐŚŶŽůŽŐLJĂŶĚŵĞƌŐŝŶŐƚŚŝĐĂů E ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ ŽŶƐŝĚĞƌĂƟŽŶƐ DƵůƟĚŝƐĐŝƉůŝŶĂƌLJDĂŶĂŐĞŵĞŶƚŽĨ^ĐůĞƌŽĚĞƌŵĂ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ WƌĂĐƟĐĂůWƌĂĐƟĐĞDĂŶĂŐĞŵĞŶƚ^ĞƐƐŝŽŶdǁŽ͗EĂǀŝŐĂƚĞ,/W ĂŶĚWƌĞǀĞŶƚƵĚŝƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ ϭ͘ϱŚƌƐ͘ ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ARHP Concurrent Abstract Session ;ηϵϳϲͲϵϴϭͿKƐƚĞŽĂƌƚŚƌŝƟƐ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ ϭ͘ϱŚƌƐ͘ ϲ͗ϯϬÖÃʹ ϵ͗ϯϬÖà /ŶĚƵƐƚƌLJͲ^ƵƉƉŽƌƚĞĚ^LJŵƉŽƐŝĂ ^ĞĞƉƌŽŐƌĂŵŬƉĂŐĞϮϯϵŽƌŶŶƵĂůDĞĞƟŶŐƉƉ ĨŽƌƚŚĞůŝƐƚŽĨƐLJŵƉŽƐŝĂ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 15 tracker MONDAY, NOVEMBER 17, 2014 Meeting At-A-Glance MONDAY, NOVEMBER 17, 2014 Location CME/Hours Time Title ϳ͗ϬϬÃʹ ϲ͗ϬϬÖà ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ džŚŝďŝƚ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ ZĞŐŝƐƚƌĂƟŽŶͿ ϳ͗ϯϬÃʹ ϴ͗ϯϬà ACR Sessions ĚƵĐĂƚŽƌ͗ƵůƟǀĂƟŶŐƚŚĞŽŵƉĞƚĞŶƚDĞĚŝĐĂůĚƵĐĂƚŽƌ͗ PM Ed ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ 'ƌŽǁŝŶŐŽŶĐĞƌŶ DĞŶŝƐĐƵƐŝŽůŽŐLJŝŶKƐƚĞŽĂƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ ZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶWĂƵů<ůĞŵƉĞƌĞƌ͕D DĞŵŽƌŝĂů>ĞĐƚƵƌĞƐŚŝƉ͗'ĞŶĞͲŶǀŝƌŽŶŵĞŶƚ/ŶƚĞƌĂĐƟŽŶƐĂƐĂ ĂƐŝƐĨŽƌhŶƌĂǀĞůůŝŶŐĚĂƉƟǀĞ/ŵŵƵŶŝƚLJĂŶĚWƌĞƉĂƌŝŶŐĨŽƌ dŽůĞƌŝnjŝŶŐdŚĞƌĂƉŝĞƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East ϭ͘ϬŚƌ͘ ϳ͗ϯϬÃʹ ϴ͗ϯϬà ARHP Sessions ^ƚĂƚƐŽŽƚĂŵƉ͗dŚĞīĞĐƚ^ŝnjĞ͗tŚĂƚ/Ɛ/ƚĂŶĚ,ŽǁĂŶzŽƵ hƐĞ/ƚ͍ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ hƉĚĂƚĞŽŶ&ŝŶĚŝŶŐƐĨƌŽŵ>ĂƌŐĞZĞŐŝƐƚƌŝĞƐ͗ŵƉŚĂƐŝƐŽŶ ,ĞĂůƚŚŝƐƉĂƌŝƟĞƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ tŚĂƚƌĞŝŽƐŝŵŝůĂƌƐ͍ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ ϭ͘ϬŚƌ͘ ϳ͗ϰϱÃʹ ϵ͗ϭϱà ACR Meet the Professor Sessions ŶŬLJůŽƐŝŶŐ^ƉŽŶĚLJůŝƟƐ͗ϮϬϭϰhƉĚĂƚĞ;ϬϯϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭ͘ϱŚƌƐ͘ WĂŝŶĞ ;>ŽďďLJͿ ĂƐŝĐ/ŵŵƵŶŽůŽŐLJĨŽƌůŝŶŝĐĂůZŚĞƵŵĂƚŽůŽŐŝƐƚƐ;ϬϯϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ KƟƐ ;>ŽďďLJͿ ŽŶƚƌŽǀĞƌƐŝĞƐŝŶ^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ;ϬϯϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ,ĂŶĐŽĐŬ ;>ŽďďLJͿ ĞƌŵĂƚŽůŽŐŝĐĂůDĂŶŝĨĞƐƚĂƟŽŶƐŽĨZŚĞƵŵĂƟĐ ŝƐĞĂƐĞƐ;ϬϯϰͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ZĞǀĞƌĞ ;>ŽďďLJͿ KƐƚĞŽĂƌƚŚƌŝƟƐ͗hƉĚĂƚĞϮϬϭϰ;ϬϯϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^ƚŽŶĞ ;>ŽďďLJͿ WƌĞŐŶĂŶĐLJĂŶĚZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϬϯϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Webster ;>ŽďďLJͿ ZĞĂĐƟǀĞƌƚŚƌŝƟƐ͗ŶhƉĚĂƚĞ;ϬϯϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Adams ;DĞnjnjĂŶŝŶĞͿ ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŚĂůůĞŶŐŝŶŐĂƐĞƐ;ϬϯϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ůĐŽƩ ;DĞnjnjĂŶŝŶĞͿ ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ŝĸĐƵůƚƚŽdƌĞĂƚ^LJƐƚĞŵŝĐ >ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ;ϬϯϵͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ŽƵŐůĂƐ ;DĞnjnjĂŶŝŶĞͿ sĂƐĐƵůŝƟƐ͗hƉĚĂƚĞ;ϬϰϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ &ĂŶĞƵŝů ;DĞnjnjĂŶŝŶĞͿ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ of Participation 16 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance MONDAY, NOVEMBER 17, 2014 Location CME/Hours Time Title ϳ͗ϰϱÃʹ ϵ͗ϰϱà ZͬZ,WtŽƌŬƐŚŽƉƐ ĚǀĂŶĐĞĚDƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ;ϮϭϰͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ ŽŵƉůĞŵĞŶƚĂƌLJĂŶĚůƚĞƌŶĂƟǀĞdŚĞƌĂƉŝĞƐŝŶZŚĞƵŵĂƟĐ ŝƐĞĂƐĞ;ϮϭϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϭ KƐƚĞŽƉŽƌŽƐŝƐ͗/ŶƚĞƌƉƌĞƟŶŐƵĂůŶĞƌŐLJyͲZĂLJďƐŽƌƉƟŽŵĞƚƌLJ ĂŶĚůŝŶŝĐĂůZŝƐŬ&ĂĐƚŽƌƐ͗dŚĞEĞǁ&ƌĂĐƚƵƌĞZŝƐŬƐƐĞƐƐŵĞŶƚ ůŐŽƌŝƚŚŵ;ϮϭϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϰ dŚĞZŚĞƵŵĂƚŽůŽŐŝĐDƵƐĐƵůŽƐŬĞůĞƚĂů^ĐƌĞĞŶŝŶŐdžĂŵ͕ ǁŝƚŚŵƉŚĂƐŝƐŽŶKďũĞĐƟǀĞŝƐĞĂƐĞͲ^ƉĞĐŝĮĐ DĞĂƐƵƌĞŵĞŶƚƐ;ϮϭϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ ϴ͗ϯϬÃʹ ϭϬ͗ϬϬà ACR Sessions ϭ͘ϱŚƌƐ͘ Z͗DĂŝŶƚĞŶĂŶĐĞŽĨĞƌƟĮĐĂƟŽŶ^ĞƐƐŝŽŶdǁŽ ŽĨdŚƌĞĞʹ^ĞƌŽŶĞŐĂƟǀĞ^ƉŽŶĚůLJŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚ /ŶĨĞĐƟŽƵƐŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ ,ŽƚdŽƉŝĐƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŽŵƉĂƌĂƟǀĞ īĞĐƟǀĞŶĞƐƐĂŶĚ,ĂƌŵƐŽĨŝŽůŽŐŝĐƐ͕ĂŶĚDĂŶĂŐĞŵĞŶƚŽĨ ŝƐĞĂƐĞͲDŽĚŝĨLJŝŶŐŶƟƌŚĞƵŵĂƟĐƌƵŐƐ;DZƐͿ FIT ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ĂŶĚŝŽůŽŐŝĐƐŝŶƚŚĞWĞƌŝŽƉĞƌĂƟǀĞWĞƌŝŽĚ :ƵǀĞŶŝůĞĞƌŵĂƚŽŵLJŽƐŝƟƐ͗ůŝŶŝĐĂů͕WĂƚŚŽŐĞŶŝĐĂŶĚ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ dŚĞƌĂƉĞƵƟĐ^ƚĂƚĞŽĨƚŚĞƌƚ WƌĂĐƟĐĂůhƐĞŽĨZĞŐŝƐƚƌŝĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϰ WƌĂĐƟĐĞ/ƐƐƵĞƐ͗WƌĂĐƟĐĞ^ƵĐĐĞƐƐŝŶĂŶŶǀŝƌŽŶŵĞŶƚŽĨ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ dƌĂŶƐŝƟŽŶ ^ƚƌĂƚĞŐŝĞƐĨŽƌĐĂĚĞŵŝĐ^ƵĐĐĞƐƐ͗dŚĞZŽĂĚŵĂƉ&ƌŽŵDĞŶƚĞĞ PM Ed ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ ƚŽDĞŶƚŽƌ ^LJƐƚĞŵƐŝŽůŽŐLJŽĨ>ƵƉƵƐEĞƉŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϯ dŚĞZ'ŽƵƚDĂŶĂŐĞŵĞŶƚ'ƵŝĚĞůŝŶĞƐ͗,ĂǀĞdŚĞLJ'ŽƩĞŶhƐ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom PM ƚŽtŚĞƌĞtĞtĂŶƚƚŽĞ͍ West of Participation Ϯ͘ϬŚƌƐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 17 tracker MONDAY, NOVEMBER 17, 2014 Meeting At-A-Glance Location Time Title ϴ͗ϯϬÃʹ ϰ͗ϬϬÖà ZͬZ,WWŽƐƚĞƌ^ĞƐƐŝŽŶ͕dŚŝĞǀĞƐ͛DĂƌŬĞƚWŽƐƚĞƌƐ and Poster Tours ďƐƚƌĂĐƚƐ;ηϵϴϮͲϭϳϵϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WŽƐƚĞƌ,Ăůů WŽƐƚĞƌ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϴ͗ϯϬʹϭϬ͗ϬϬÃͿ CME/Hours of Participation Ϯ͘ϬŚƌƐ͘ ;džŚŝďŝƚ,ĂůůͿ Poster Presenters Available ϵ͗ϬϬʹϭϭ͗ϬϬà Guided Poster Tours ϵ͗ϬϬʹϵ͗ϰϱà ϯϭϯʹƉŝĚĞŵŝŽůŽŐLJĂŶĚ,ĞĂůƚŚ^ĞƌǀŝĐĞƐZĞƐĞĂƌĐŚWŽƐƚĞƌ Tour ϯϭϰʹ&ŝďƌŽŵLJĂůŐŝĂ͕^ŽŌdŝƐƐƵĞŝƐŽƌĚĞƌƐ͕ZĞŐŝŽŶĂůĂŶĚ ^ƉĞĐŝĮĐůŝŶŝĐĂůWĂŝŶ^LJŶĚƌŽŵĞƐWŽƐƚĞƌdŽƵƌ ϯϭϱʹ/ŵĂŐŝŶŐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞƐWŽƐƚĞƌdŽƵƌ ϯϭϲʹWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ ϯϭϳʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ ϯϭϴʹ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐĂŶĚZĂLJŶĂƵĚ͛Ɛʹ WĂƚŚŽŐĞŶĞƐŝƐ͕ŶŝŵĂůDŽĚĞůƐĂŶĚ'ĞŶĞƟĐƐWŽƐƚĞƌdŽƵƌ ϭϬ͗ϭϱʹϭϭ͗ϬϬà ϯϭϵʹWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ ϯϮϬʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐdƌĞĂƚŵĞŶƚʹ^ŵĂůůDŽůĞĐƵůĞƐ͕ ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJWŽƐƚĞƌdŽƵƌ ϯϮϭʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ ϯϮϮʹ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ͗ůŝŶŝĐĂů ƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚWŽƐƚĞƌdŽƵƌ ϯϮϯʹ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌ Tour ϯϮϰʹsĂƐĐƵůŝƟƐWŽƐƚĞƌdŽƵƌ ϵ͗ϬϬÃʹ ϭϬ͗ϬϬà ACR Sessions ϭ͘ϬŚƌ͘ &ƵŶĐƟŽŶĂů'ĞŶŽŵŝĐƐŽĨZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗&ƌŽŵ'ĞŶĞƐƚŽ &ƵŶĐƟŽŶƚŽdŚĞƌĂƉLJ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ ϭϬϰ >ĞŐŝƐůĂƟǀĞhƉĚĂƚĞ͗ŚĂƚǁŝƚŚŽŶŐƌĞƐƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ WƌŽƐƚŚĞƟĐĞǀŝĐĞ/ŶĨĞĐƟŽŶƐ͕Žƌ/ŶĨĞĐƟŽŶĂƐĂdŚƌĞĂƚƚŽƚŚĞ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East ŝŽŶŝĐDĂŶ ^ŽĐŝĂůDĞĚŝĂŽŽƚĂŵƉ͗ůŽŐŐŝŶŐĨŽƌĞŐŝŶŶĞƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ ϵ͗ϬϬÃʹ ϭϬ͗ϬϬà ARHP Session Z,WŝƐƟŶŐƵŝƐŚĞĚ>ĞĐƚƵƌĞƌ͗DĂŝŶƚĂŝŶŝŶŐ,ĞĂůƚŚĂŶĚ tĞůůͲĞŝŶŐĞƐƉŝƚĞ>ŝǀŝŶŐǁŝƚŚĂZŚĞƵŵĂƟĐŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ ϭϬ͗ϬϬÃʹ Exhibits ϱ͗ϬϬÖà džŚŝďŝƚ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϭϬ͗ϬϬʹϭϭ͗ϬϬÃͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů džŚŝďŝƚ,ĂůůŌĞƌŶŽŽŶ^ŶĂĐŬƌĞĂŬ;Ϯ͗ϬϬʹϯ͗ϬϬÖÃͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ ϭ͘ϬŚƌ͘ 18 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance Time MONDAY, NOVEMBER 17, 2014 Location Title CME/Hours of Participation ϭϬ͗ϯϬÃʹ Exhibits ϭϭ͗ϭϱà /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϯϵͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ ϭϬ͗ϯϬÃʹ ZtŽƌŬƐŚŽƉƐ ϭϮ͗ϯϬÖà ,ŝƐƚŽƉĂƚŚŽůŽŐLJŽĨsĂƐĐƵůŝƟƐ;ϮϭϴͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ <ŶĞĞƌĂĐĞƐ͕&ŽŽƚKƌƚŚŽƐĞƐĂŶĚ^ŚŽĞ'ĞĂƌĨŽƌDĂŶĂŐŝŶŐ <ŶĞĞKƐƚĞŽĂƌƚŚƌŝƟƐ;ϮϭϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ DƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ;ϮϮϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ZĞŶĂů,ŝƐƚŽƉĂƚŚŽůŽŐLJŝŶ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐĂŶĚ sĂƐĐƵůŝƟƐ;ϮϮϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϰ Ϯ͘ϬŚƌƐ͘ ϭϱϮ ϭϱϵ ϭϲϭ ϭϭ͗ϬϬÃʹ ACR Sessions EŽŽŶ Z/ŵŵƵŶŽůŽŐLJhƉĚĂƚĞ͗/ŶŶĂƚĞ>LJŵƉŚŽŝĚĞůůƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ Z<ŶŽǁůĞĚŐĞŽǁů͗&ŝŶĂůZŽƵŶĚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom West ϭ͘ϬŚƌ͘ ϭϭ͗ϬϬÃʹ ARHP Sessions EŽŽŶ ǀŝĚĞŶĐĞŽĨƚŚĞĞŶĞĮƚƐĂŶĚZŝƐŬƐŽĨĂŶŶĂďŝƐĂŶĚ ĂŶŶĂďŝŶŽŝĚƐĨŽƌdƌĞĂƟŶŐŚƌŽŶŝĐWĂŝŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϵ /ŵŵƵŶŽůŽŐLJŽŽƚĂŵƉ//͗dŚĞĂƐŝĐƐŽĨƵƚŽŝŵŵƵŶŝƚLJĂŶĚ /ŵŵƵŶŽĚĞĮĐŝĞŶĐLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ ^ƚĂƚƐŽŽƚĂŵƉ͗^ƚĂƟƐƟĐĂůŶĂůLJƐŝƐŽĨKƌĚŝŶĂůĂƚĂ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ ϭ͘ϬŚƌ͘ ϭϭ͗ϬϬÃʹ ZWůĞŶĂƌLJ^ĞƐƐŝŽŶ//͗ŝƐĐŽǀĞƌLJϮϬϭϰ ϭϮ͗ϯϬÖà ďƐƚƌĂĐƚƐ;ηϭϳϵϰͲϭϳϵϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϭ͘ϱŚƌƐ͘ ϭϭ͗ϯϬÃʹ Exhibits ϭϮ͗ϭϱÖà /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϰϬϭͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ EŽŽŶʹ Ϯ͗ϬϬÖà EĞƚǁŽƌŬŝŶŐǀĞŶƚ Z,WEĞƚǁŽƌŬŝŶŐĂƚEŽŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Commonwealth Ballroom ϭϮ͗ϯϬÖÃʹ Exhibits ϭ͗ϭϱÖà /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϯϵͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 19 tracker MONDAY, NOVEMBER 17, 2014 Time Meeting At-A-Glance Location Title ϭϮ͗ϰϱÖÃʹ ACR Meet the Professor Sessions Ϯ͗ϭϱÖà ĚƵůƚ/ŶŇĂŵŵĂƚŽƌLJDLJŽƉĂƚŚLJ;ϬϰϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJĨŽƌĚƵůƚZŚĞƵŵĂƚŽůŽŐŝƐƚƐ;ϬϰϮͿ Pd PS ͘ ͘ ͘ WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ;ϬϰϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŝŽůŽŐŝĐĂůŐĞŶƚƐ;ϬϰϰͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŚĂůůĞŶŐŝŶŐĂƐĞƐ;ϬϰϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^ĐůĞƌŽĚĞƌŵĂDŝŵŝĐƐ;ϬϰϲͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^Ɵůů͛ƐŝƐĞĂƐĞĂŶĚƵƚŽŝŶŇĂŵŵĂƚŽƌLJ^LJŶĚƌŽŵĞƐ;ϬϰϳͿ͘ ͘ ͘ ͘ ͘ ͘ ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ĞŶƚƌĂůEĞƌǀŽƵƐ ^LJƐƚĞŵ;ϬϰϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WĂŝŶĞ ;>ŽďďLJͿ KƟƐ ;>ŽďďLJͿ ,ĂŶĐŽĐŬ ;>ŽďďLJͿ ZĞǀĞƌĞ ;>ŽďďLJͿ ^ƚŽŶĞ ;>ŽďďLJͿ Webster ;>ŽďďLJͿ Adams ;DĞnjnjĂŶŝŶĞͿ CME/Hours of Participation ϭ͘ϱŚƌƐ͘ ůĐŽƩ ;DĞnjnjĂŶŝŶĞͿ ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͗ŝƐĞĂƐĞ^ƚĂŐŝŶŐĂŶĚ^ƵďƐĞƫŶŐŝŶ ůŝŶŝĐĂůWƌĂĐƟĐĞ ;ϬϰϵͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ŽƵŐůĂƐ ;DĞnjnjĂŶŝŶĞͿ &ĂŶĞƵŝů sĂƐĐƵůŝƟƐDŝŵŝĐƐ;ϬϱϬͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;DĞnjnjĂŶŝŶĞͿ ϭ͗ϬϬÖÃʹ Ϯ͗ϬϬÖà ACR Sessions PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ůĂƐƐŝĮĐĂƟŽŶƌŝƚĞƌŝĂĨŽƌ'ŽƵƚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ůĂƐƐŝĮĐĂƟŽŶƌŝƚĞƌŝĂĨŽƌDLJŽƐŝƟƐ EĞŽŶĂƚĂů>ƵƉƵƐ͗&ƌŽŵĞŶĐŚƚŽĞĚƐŝĚĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ZŚĞƵŵĂƚŽůŽŐLJŽŶƚŚĞ^ƚƌĞĞƚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ dĞůŽŵĞƌĞƐ͕dĞůŽŵĞƌĂƐĞĂŶĚƚŚĞŐŝŶŐ/ŵŵƵŶĞ^LJƐƚĞŵ ϮϬϱ ϭϬϳ Ballroom East Ballroom West ͘ ͘ ͘ ϱϮ ϭ͗ϭϱÖÃʹ ϯ͗ϭϱÖà ZtŽƌŬƐŚŽƉƐ :ŽŝŶƚ/ŶũĞĐƟŽŶdĞĐŚŶŝƋƵĞƐ;ϮϮϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ DĂŐŶĞƟĐZĞƐŽŶĂŶĐĞ/ŵĂŐŝŶŐŝŶƚŚĞŝĂŐŶŽƐŝƐĂŶĚ DĂŶĂŐĞŵĞŶƚŽĨ^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ͗ůŝŶŝĐŝĂŶ͛Ɛ 'ƵŝĚĞ;ϮϮϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ ^LJŶŽǀŝĂů&ůƵŝĚŶĂůLJƐŝƐĂŶĚƌLJƐƚĂů/ĚĞŶƟĮĐĂƟŽŶ;ϮϮϰͿ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϭ ϭ͗ϯϬÖÃʹ Ϯ͗ϭϱÖà Exhibits /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϰϬϭͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ Ϯ͗ϯϬÖÃʹ ϯ͗ϭϱÖà Exhibits /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϯϵͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ ϭ͘ϬŚƌ͘ Ϯ͘ϬŚƌƐ͘ 20 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance MONDAY, NOVEMBER 17, 2014 Location CME/Hours Time Title Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ACR Sessions ůŝŶŝĐĂůŚĂůůĞŶŐĞƐŝŶ^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ͗EĞƵƌŽůŽŐŝĐĂů ŽŵƉůŝĐĂƟŽŶƐĂŶĚ>LJŵƉŚŽŵĂZŝƐŬ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ &ŽƌĞĨƌŽŶƚƐŝŶ>ƵƉƵƐEĞƉŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East /ŶƐŝŐŚƚŝŶƚŽ>ƵŶŐ&ŝďƌŽƐŝƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ ϭ͘ϱŚƌƐ͘ Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ACR Concurrent Abstract Sessions ;ηϭϴϬϬͲϭϴϬϱͿƉŝĚĞŵŝŽůŽŐLJĂŶĚWƵďůŝĐ,ĞĂůƚŚ//͗ KƐƚĞŽĂƌƚŚƌŝƟƐ͕^ĞĚĞŶƚĂƌLJĞŚĂǀŝŽƌĂŶĚDŽƌĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϭϴϬϲͲϭϴϭϭͿ,ĞĂůƚŚ^ĞƌǀŝĐĞƐZĞƐĞĂƌĐŚ͗/ŵƉƌŽǀŝŶŐ ůŝŶŝĐĂůWƌĂĐƟĐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϭϴϭϮͲϭϴϭϳͿ/ŶŶĂƚĞ/ŵŵƵŶŝƚLJĂŶĚZŚĞƵŵĂƟĐŝƐĞĂƐĞ ͘ ͘ ͘ ;ηϭϴϭϴͲϭϴϮϯͿKƐƚĞŽĂƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ/͗/ŵĂŐŝŶŐ ŝŶKƐƚĞŽĂƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϭϴϮϰͲϭϴϮϵͿWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJʹClinical ĂŶĚdŚĞƌĂƉĞƵƟĐƐƉĞĐƚƐ͗WĞĚŝĂƚƌŝĐ^LJƐƚĞŵŝĐ>ƵƉƵƐ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Erythematosus ;ηϭϴϯϬͲϭϴϯϱͿYƵĂůŝƚLJDĞĂƐƵƌĞƐĂŶĚYƵĂůŝƚLJŽĨĂƌĞ ͘ ͘ ͘ ͘ ͘ ;ηϭϴϯϲͲϭϴϰϭͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ///͗ DĂůŝŐŶĂŶĐŝĞƐ͕sĂĐĐŝŶĂƟŽŶƐ͕WƌĞŐŶĂŶĐLJĂŶĚ^ƵƌŐĞƌLJ ͘ ͘ ͘ ͘ ͘ ;ηϭϴϰϮͲϭϴϰϳͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕ ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJ///͗/ŶŶŽǀĂƟǀĞdŚĞƌĂƉĞƵƟĐ ^ƚƌĂƚĞŐŝĞƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϭϴϰϴͲϭϴϱϯͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ IIIʹůŝŶŝĐĂůƐƉĞĐƚƐŽĨWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϭϴϱϰͲϭϴϱϵͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹClinical ƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚ͗ŽŵƉůŝĐĂƟŽŶƐŽĨ^LJƐƚĞŵŝĐ>ƵƉƵƐ Erythematosus ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭ͘ϱŚƌƐ͘ ;ηϭϴϲϬͲϭϴϲϱͿsĂƐĐƵůŝƟƐ// of Participation Ϯϱϯ ϭϲϬ ϭϱϲ ϭϬϰ ϭϱϳ ϭϱϯ ϮϭϬ džŚŝďŝƚ,Ăůů Ϯϱϴ Ballroom West ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ACR/ARHP Combined Abstract Session ;ηϭϴϲϲͲϭϴϳϭͿZͬZ,WŽŵďŝŶĞĚďƐƚƌĂĐƚ^ĞƐƐŝŽŶ͗ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ WĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJ ϭ͘ϱŚƌƐ͘ Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ARHP Sessions ůƚĞƌŶĂƟǀĞDĞĚŝĐŝŶĞ͗WƌĞƐĞŶƟŶŐƚŚĞǀŝĚĞŶĐĞĨŽƌZŚĞƵŵĂƟĐ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ ŽŶĚŝƟŽŶƐ ŝŽŵĂƌŬĞƌƐŝŶZŚĞƵŵĂƟĐĂƌĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ ^ƚĂƚƐŽŽƚĂŵƉ͗ĂůůƚŽŝŵƐĨŽƌZĞƐĞĂƌĐŚĞƌƐ͊Ŷ /ŶƚĞƌĂĐƟǀĞ^ĞƐƐŝŽŶƚŽKďƚĂŝŶ&ĞĞĚďĂĐŬŽŶzŽƵƌ^ƉĞĐŝĮĐ ŝŵƐ^ĞĐƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ dŚƌŝǀŝŶŐǁŝƚŚZŚĞƵŵĂƟĐŝƐĞĂƐĞ͗ƵůƟǀĂƟŶŐZĞƐŝůŝĞŶĐĞ ͘ ͘ ͘ ͘ Ϯϱϱ ϭ͘ϱŚƌƐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 21 tracker Meeting At-A-Glance MONDAY, NOVEMBER 17, 2014 Location Time Title ϯ͗ϯϬÖÃʹ ϰ͗ϭϱÖà Exhibits /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϰϬϭͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ ϰ͗ϬϬÖÃʹ ϲ͗ϬϬÖà ZͬZ,WtŽƌŬƐŚŽƉƐ ĞƌŵĂƚŽƉĂƚŚŽůŽŐLJŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϮϮϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ :ŽŝŶƚ/ŶũĞĐƟŽŶƐ;<ŶĞĞ͕ŶŬůĞ͕^ŚŽƵůĚĞƌĂŶĚtƌŝƐƚͿ;ϮϮϲͿ͘ ͘ ͘ ͘ ͘ D,YͬZW/ϯĂŶĚZ,hDK͗YƵĂŶƟƚĂƟǀĞ͕^ƚĂŶĚĂƌĚ͕ ^ĐŝĞŶƟĮĐ^ƵŵŵĂƌŝĞƐŽĨWĂƟĞŶƚ,ŝƐƚŽƌLJĂŶĚWŚLJƐŝĐĂůdžĂŵ͕ ƚŽǁĂƌĚĞƩĞƌůŝŶŝĐĂůĞĐŝƐŝŽŶƐĂŶĚKƵƚĐŽŵĞƐ;ϮϮϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ DƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽŶŽŐƌĂƉŚLJ͗ĂƐŝĐ;ϮϮϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϭ ϭϱϮ ACR Session ůŝŶŝĐŽƉĂƚŚŽůŽŐŝĐŽŶĨĞƌĞŶĐĞ ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ACR Sessions ĂƌĞĞƌKƉƉŽƌƚƵŶŝƟĞƐŝŶZŚĞƵŵĂƚŽůŽŐLJ͗DĂŬŝŶŐ a Choice ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϰ ƵƌďƐŝĚĞŽŶƐƵůƚƐʹƐŬƚŚĞdžƉĞƌƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom West &ŝďƌŽƟĐŽŵƉůŝĐĂƟŽŶƐŽĨ^ĐůĞƌŽĚĞƌŵĂ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϬ dŚĞZŽůĞŽĨŽŶĞŝŶƚŚĞWĂƚŚŽŐĞŶĞƐŝƐŽĨKƐƚĞŽĂƌƚŚƌŝƟƐ ͘ ͘ ͘ ϭϬϮ dƌĞĂƟŶŐWĂŝŶŽĞƐŶ͛ƚ,ĂǀĞƚŽĞĂWĂŝŶ͗WƌĂĐƟĐĂůƉƉƌŽĂĐŚĞƐ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ PM ƚŽWĂŝŶDĂŶĂŐĞŵĞŶƚ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ FIT of Participation Ϯ͘ϬŚƌƐ͘ ϭϱϰ ϭϱϵ ϰ͗ϯϬÖÃʹ ϱ͗ϯϬÖà PM Ed CME/Hours ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East ϭ͘ϬŚƌ͘ ϭ͘ϱŚƌƐ͘ 22 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance MONDAY, NOVEMBER 17, 2014 Location CME/Hours Time Title ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ACR Concurrent Abstract Sessions ϭ͘ϱŚƌƐ͘ ;ηϭϴϳϮͲϭϴϳϳͿƉŝĚĞŵŝŽůŽŐLJĂŶĚWƵďůŝĐ,ĞĂůƚŚ///͗'ŽƵƚĂŶĚ ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϯ ;ηϭϴϳϴͲϭϴϴϯͿ&ŝďƌŽŵLJĂůŐŝĂ͕^ŽŌdŝƐƐƵĞŝƐŽƌĚĞƌƐ͕ZĞŐŝŽŶĂů ĂŶĚ^ƉĞĐŝĮĐůŝŶŝĐĂůWĂŝŶ^LJŶĚƌŽŵĞƐ//͗ůŝŶŝĐĂů PM ϭϬϰ WĞƌƐƉĞĐƟǀĞƐ ;ηϭϴϴϰͲϭϴϴϵͿ'ĞŶĞƟĐƐ͕'ĞŶŽŵŝĐƐĂŶĚWƌŽƚĞŽŵŝĐƐ/͗ ƉŝŐĞŶĞƟĐDĞĐŚĂŶŝƐŵƐŝŶƵƚŽŝŵŵƵŶŝƚLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ ;ηϭϴϵϬͲϭϴϵϱͿ/ŵĂŐŝŶŐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ͗yͲƌĂLJ͕ DZ/ĂŶĚd ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ ;ηϭϴϵϲͲϭϵϬϭͿWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJʹWĂƚŚŽŐĞŶĞƐŝƐĂŶĚ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ 'ĞŶĞƟĐƐ ;ηϭϵϬϮͲϭϵϬϳͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ/s͗ WƌŽŵŝƐŝŶŐŝŽŵĂƌŬĞƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϴ ;ηϭϵϬϴͲϭϵϭϯͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕ ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJ/s͗^ĂĨĞƚLJŽĨŝŽůŽŐŝĐƐĂŶĚ^ŵĂůů DŽůĞĐƵůĞƐŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹĂƌĚŝŽǀĂƐĐƵůĂƌĂŶĚ KƚŚĞƌ^LJƐƚĞŵƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ηϭϵϭϰͲϭϵϭϵͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐʹ WĂƚŚŽŐĞŶĞƐŝƐ͕ƟŽůŽŐLJ͗&ƌŽŵ'ĞŶĞƐƚŽLJƚŽŬŝŶĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ ;ηϭϵϮϬͲϭϵϮϱͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹClinical ƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚ͗ŝŽŵĂƌŬĞƌƐŝŶ^LJƐƚĞŵŝĐ>ƵƉƵƐ Erythematosus ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ ;ηϭϵϮϲͲϭϵϯϭͿ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐ ĂŶĚZĂLJŶĂƵĚ͛ƐʹůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdŚĞƌĂƉĞƵƟĐƐ//͗ ƉƉƌŽĂĐŚĞƐƚŽĂƌĚŝĂĐĂŶĚsĂƐĐƵůĂƌDĂŶŝĨĞƐƚĂƟŽŶƐŝŶ ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ of Participation ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 23 tracker MONDAY, NOVEMBER 17, 2014 Meeting At-A-Glance Time Title ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ACR Meet the Professor Sessions ŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞ;ϬϱϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ĞŚĕĞƚ͛Ɛ^LJŶĚƌŽŵĞ;ϬϱϮͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ /ŵŵƵŶŽĚĞĮĐŝĞŶĐLJ^LJŶĚƌŽŵĞƐ;ϬϱϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ /ŶĨĞĐƟŽŶƐǁŝƚŚŝŽůŽŐŝĐƐ;ϬϱϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ DLJŽƉĂƚŚLJ͗/ƐƐƵĞƐŝŶŝĂŐŶŽƐŝƐĂŶĚdƌĞĂƚŵĞŶƚ;ϬϱϱͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WƵůŵŽŶĂƌLJDĂŶŝĨĞƐƚĂƟŽŶƐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞ;ϬϱϲͿ͘ ͘ ͘ ͘ ͘ ͘ ZĂLJŶĂƵĚ͛ƐĂŶĚŝŐŝƚĂů/ƐĐŚĞŵŝĂ;ϬϱϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Location WĂŝŶĞ ;>ŽďďLJͿ KƟƐ ;>ŽďďLJͿ ,ĂŶĐŽĐŬ ;>ŽďďLJͿ ZĞǀĞƌĞ ;>ŽďďLJͿ ^ƚŽŶĞ ;>ŽďďLJͿ Webster ;>ŽďďLJͿ Adams ;DĞnjnjĂŶŝŶĞͿ CME/Hours of Participation ϭ͘ϱŚƌƐ͘ ^ĂĨĞƚLJŽĨƌƵŐƐhƐĞĚƚŽdƌĞĂƚZŚĞƵŵĂƚŽŝĚ ƌƚŚƌŝƟƐ;ϬϱϴͿ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ůĐŽƩ ;DĞnjnjĂŶŝŶĞͿ ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗>ƵƉƵƐEĞƉŚƌŝƟƐ;ϬϱϵͿ ͘ ͘ ͘ ͘ ͘ ͘ ŽƵŐůĂƐ ;DĞnjnjĂŶŝŶĞͿ sĂƐĐƵůŝƟƐ͗&ĂĐƚŽƌƐdŚĂƚ/ŶŇƵĞŶĐĞŝƐĞĂƐĞWĂƩĞƌŶƐ;ϬϲϬͿ͘ ͘ ͘ ͘ ͘ &ĂŶĞƵŝů ;DĞnjnjĂŶŝŶĞͿ ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ARHP Sessions ĞƐƚWƌĂĐƟĐĞƐŽĨdŽƚĂů<ŶĞĞƌƚŚƌŽƉůĂƐƚLJʹ&ƌŽŵ^ƵƌŐĞƌLJ ƚŽZĞŚĂďŝůŝƚĂƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ &ƌŽŵ/ŶŇĂŵŵĂƟŽŶƚŽƚŚĞƌŽƐĐůĞƌŽƐŝƐ͗dŚĞĂƐĞŽĨ /ŶŇĂŵŵĂƚŽƌLJZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ZŽůĞŽĨEƵƚƌŝƟŽŶŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ dŚĞŵĞƌŐŝŶŐĞŵĂŶĚĨŽƌDĞĚŝĐŝŶĂůĂŶŶĂďŝƐďLJzŽƵŶŐ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Adults and Beyond ϭ͘ϱŚƌƐ͘ Ϯϱϰ Ϯϱϲ Ϯϱϳ Ϯϱϱ ARHP Concurrent Abstract Sessions ;ηϭϵϯϮͲϭϵϯϳͿ,ĞĂůƚŚŝƐƉĂƌŝƟĞƐͬ^ŽĐŝĂůĞƚĞƌŵŝŶĂŶƚƐ PM Ed ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ ŽĨ,ĞĂůƚŚ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ ϭ͘ϱŚƌƐ͘ 24 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance MONDAY & TUESDAY, NOVEMBER 17 – 18, 2014 Location Time Title ϲ͗ϯϬÖÃʹ ϳ͗ϰϱÖà ^ƚƵĚLJ'ƌŽƵƉƐ ZDƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞdĂƐŬ&ŽƌĐĞ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ĂƉŝůůĂƌŽƐĐŽƉLJŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ŚŝůĚŚŽŽĚsĂƐĐƵůŝƟƐ^ƚƵĚLJ'ƌŽƵƉ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ ůŝŶŝĐĂůŶĂƚŽŵLJ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ƌLJƐƚĂů^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ĞŐŽƐŝƐĞĂƐĞ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ,LJƉĞƌŵŽďŝůŝƚLJ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ /ŶƚĞƐƟŶĂů>ƵŶŐŝĞƐĞĂƐĞ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ DĂĐƌŽƉŚĂŐĞĐƟǀĂƟŽŶ^LJŶĚƌŽŵĞ;D^Ϳ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ DLJŽƐŝƟƐ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ KƐƚĞŽĂƌƚŚƌŝƟƐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐŝƐƚƐ/ŶƚĞƌĞƐƚĞĚŝŶDĞĚŝĂůĚƵĐĂƟŽŶ ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ dŚĞ͞tŚLJĂŶĚ,Žǁ͟ŽĨŝƐĞĂƐĞƌŝƚĞƌŝĂ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ sĞƚĞƌĂŶƐīĂŝƌƐZŚĞƵŵĂƚŽůŽŐLJ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ CME/Hours of Participation ϭϬϵ ϭϱϳ Ϯϱϲ Ϯϱϱ Ϯϱϵ ϭϬϮ ϭϬϳ ϭϬϰ ϭϲϬ ϭϱϲ ϭϱϯ Ϯϱϳ ϭϱϭ Ϯϱϰ ϮϬϰ TUESDAY, NOVEMBER 18, 2014 Location Time Title ϳ͗ϬϬÃʹ ϲ͗ϬϬÖà ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ džŚŝďŝƚ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ ZĞŐŝƐƚƌĂƟŽŶͿ ϳ͗ϯϬÃʹ ϴ͗ϯϬà ACR Sessions 'ůLJĐŽƐLJůĂƟŽŶĂŶĚ'ůLJĐĂŶŝŶĚŝŶŐWƌŽƚĞŝŶƐŝŶ /ŵŵƵŶĞ&ƵŶĐƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ ,ĞƉĂƟƟƐŝŶϮϬϭϰ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom West E ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ WĂƟĞŶƚĐĐĞƐƐƚŽŝŽůŽŐŝĐƐĐƌŽƐƐƚŚĞ'ůŽďĞ ϳ͗ϯϬÃʹ ϴ͗ϯϬà ARHP Sessions ůŝŶŝĐĂů&ĞĂƚƵƌĞƐŽĨĞŶƚƌĂůEĞƌǀŽƵƐ^LJƐƚĞŵ>ƵƉƵƐ ĂŶĚŝĂŐŶŽƐŝƐŽĨŽŐŶŝƟǀĞĞĮĐŝƚƐĂŶĚWƐLJĐŚŝĂƚƌŝĐ ŝƐŽƌĚĞƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ DƵƐĐůĞĂŶĚĚŝƉŽƐĞdŝƐƐƵĞŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ͗ >ŽĐĂƟŽŶŝƐǀĞƌLJƚŚŝŶŐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ CME/Hours of Participation ϭŚƌ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 25 tracker TUESDAY, NOVEMBER 18, 2014 Meeting At-A-Glance Time Title ϳ͗ϰϱÃʹ ϵ͗ϭϱà ACR Meet the Professor Sessions ŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞ;ϬϲϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ŽŶƚƌŽǀĞƌƐŝĞƐŝŶ^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ;ϬϲϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ &ŽŽƚǁĞĂƌŝŶKƌƚŚŽĂƌƚŚƌŝƟƐ;ϬϲϯͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ KƐƚĞŽƉŽƌŽƐŝƐ͗EŽǀĞůdƌĞĂƚŵĞŶƚƐ;ϬϲϰͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WĞĚŝĂƚƌŝĐƐ͗WĞƌŝŽĚŝĐ&ĞǀĞƌƐŝŶŚŝůĚƌĞŶ;ϬϲϱͿ Pd ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗KƵƚĐŽŵĞDĞĂƐƵƌĞƐŝŶůŝŶŝĐĂů WƌĂĐƟĐĞ;ϬϲϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^ĂĨĞƚLJŽĨƌƵŐƐhƐĞĚƚŽdƌĞĂƚZŚĞƵŵĂƚŽŝĚ ƌƚŚƌŝƟƐ;ϬϲϳͿ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ĞŶƚƌĂůEĞƌǀŽƵƐ ^LJƐƚĞŵ;ϬϲϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͗ŝƐĞĂƐĞ^ƚĂŐŝŶŐĂŶĚ^ƵďƐĞƫŶŐŝŶ ůŝŶŝĐĂůWƌĂĐƟĐĞ;ϬϲϵͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ sĂƐĐƵůŝƟƐ͗&ĂĐƚŽƌƐdŚĂƚ/ŶŇƵĞŶĐĞŝƐĞĂƐĞWĂƩĞƌŶƐ;ϬϳϬͿ͘ ͘ ͘ ͘ ͘ ϳ͗ϰϱÃʹ ϵ͗ϰϱà ϴ͗ϯϬÃʹ ϭϬ͗ϬϬà ZͬZ,WtŽƌŬƐŚŽƉƐ ĚǀĂŶĐĞĚDƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ͗/ŵĂŐĞKƉƟŵŝnjĂƟŽŶ ĂŶĚWĂƚŚŽůŽŐLJZĞĐŽŐŶŝƟŽŶ;ϮϮϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ĂƐŝĐ^ƚĂƟƐƟĐĂůŽŶĐĞƉƚƐĨŽƌƚŚĞDĞĚŝĐĂůZĞƐĞĂƌĐŚĞƌ;ϮϯϬͿ͘ ͘ :ŽŝŶƚ/ŶũĞĐƟŽŶƐ;<ŶĞĞ͕ŶŬůĞ͕^ŚŽƵůĚĞƌĂŶĚtƌŝƐƚͿ;ϮϯϭͿ͘ ͘ ͘ ͘ ͘ DĂŐŶĞƟĐZĞƐŽŶĂŶĐĞ/ŵĂŐŝŶŐŽĨWĞƌŝƉŚĞƌĂů:ŽŝŶƚƐŝŶ ZŚĞƵŵĂƚŽůŽŐLJWƌĂĐƟĐĞ;ϮϯϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ACR Sessions ŝŽĞŶĞƌŐĞƟĐƐĂŶĚŶĞƌŐLJZĞŐƵůĂƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Z͗DĂŝŶƚĞŶĂŶĐĞŽĨĞƌƟĮĐĂƟŽŶ^ĞƐƐŝŽŶdŚƌĞĞ of Three ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ĚƵĐĂƚŽƌ͗ŝƌĞĐƚKďƐĞƌǀĂƟŽŶŽĨůŝŶŝĐĂů^ŬŝůůƐ͗ĚƵĐĂƟŽŶĂůůLJ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ PM Ed /ŶĚŝĐĂƚĞĚ͕dŚĞƌĂƉĞƵƟĐĂůůLJZĞƋƵŝƌĞĚ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ DĂĐƌŽƉŚĂŐĞƐ'ŽŶĞtŝůĚ DLJŽƐŝƟƐDŝŵŝĐƐ͗ůŝŶŝĐĂůĂŶĚDŽůĞĐƵůĂƌŝĂŐŶŽƐŝƐ ͘͘͘͘͘͘͘ ZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶ͗ŝƐĞĂƐĞdĂƌŐĞƚĞĚ ZĞƐĞĂƌĐŚ͗^ƉĞĐŝĂů^ĞƐƐŝŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ZŝƐŬĂŶĚZŝƐŬDĂŶĂŐĞŵĞŶƚŽĨĂƌĚŝŽǀĂƐĐƵůĂƌŝƐĞĂƐĞŝŶ WĂƟĞŶƚƐǁŝƚŚZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐĂŶĚKƚŚĞƌ^LJƐƚĞŵŝĐ ZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ Location WĂŝŶĞ ;>ŽďďLJͿ KƟƐ ;>ŽďďLJͿ ,ĂŶĐŽĐŬ ;>ŽďďLJͿ ZĞǀĞƌĞ ;>ŽďďLJͿ ^ƚŽŶĞ ;>ŽďďLJͿ Webster ;>ŽďďLJͿ Adams ;DĞnjnjĂŶŝŶĞͿ ůĐŽƩ ;DĞnjnjĂŶŝŶĞͿ ŽƵŐůĂƐ ;DĞnjnjĂŶŝŶĞͿ &ĂŶĞƵŝů ;DĞnjnjĂŶŝŶĞͿ CME/Hours of Participation ϭ͘ϱŚƌƐ͘ Ϯ͘ϬŚƌƐ͘ ϭϱϵ ϭϲϭ ϭϱϮ ϭϱϰ Ϯϱϯ ϱϮ ϭϬϮ ϭϬϰ Ballroom East ϭϱϯ džŚŝďŝƚ,Ăůů ϭ͘ϱŚƌƐ͘ 26 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance TUESDAY, NOVEMBER 18, 2014 Location Time Title ϴ͗ϯϬÃʹ ϰ͗ϬϬÖà ZͬZ,WWŽƐƚĞƌ^ĞƐƐŝŽŶ͕>ĂƚĞͲƌĞĂŬŝŶŐĂŶĚdŚŝĞǀĞƐ͛ Market Posters and Poster Tours ďƐƚƌĂĐƚƐ;ηϭϵϯϴͲϮϳϴϬͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WŽƐƚĞƌ,Ăůů CME/Hours of Participation Ϯ͘ϬŚƌƐ͘ ;džŚŝďŝƚ,ĂůůͿ WŽƐƚĞƌ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϴ͗ϯϬʹϭϬ͗ϬϬÃͿ Poster Presenters Available ϵ͗ϬϬʹϭϭ͗ϬϬà Guided Poster Tours ϵ͗ϬϬʹϵ͗ϰϱà ϯϮϱʹKƐƚĞŽĂƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ ϯϮϲʹYƵĂůŝƚLJDĞĂƐƵƌĞƐĂŶĚYƵĂůŝƚLJŽĨĂƌĞWŽƐƚĞƌdŽƵƌ ϯϮϳʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌdŽƵƌ ϯϮϴʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐdƌĞĂƚŵĞŶƚʹ^ŵĂůůDŽůĞĐƵůĞƐ͕ ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJWŽƐƚĞƌdŽƵƌ ϯϮϵʹ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ͗ůŝŶŝĐĂů ƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚWŽƐƚĞƌdŽƵƌ ϯϯϬʹ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐĂŶĚZĂLJŶĂƵĚ͛Ɛ ʹůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdŚĞƌĂƉĞƵƟĐƐWŽƐƚĞƌdŽƵƌ ϭϬ͗ϭϱʹϭϭ͗ϬϬà ϯϯϭʹƉŝĚĞŵŝŽůŽŐLJĂŶĚ,ĞĂůƚŚ^ĞƌǀŝĐĞƐZĞƐĞĂƌĐŚ WŽƐƚĞƌdŽƵƌ ϯϯϮʹ,ĞĂůƚŚ^ĞƌǀŝĐĞƐZĞƐĞĂƌĐŚWŽƐƚĞƌdŽƵƌ ϯϯϯʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ,ƵŵĂŶƟŽůŽŐLJĂŶĚ WĂƚŚŽŐĞŶĞƐŝƐWŽƐƚĞƌdŽƵƌ ϯϯϰʹZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐdƌĞĂƚŵĞŶƚʹ^ŵĂůůDŽůĞĐƵůĞƐ͕ ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJWŽƐƚĞƌdŽƵƌ ϯϯϱʹZŚĞƵŵĂƚŽůŽŐLJϯϲϬWŽƐƚĞƌdŽƵƌ ϯϯϲʹ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗ůŝŶŝĐĂůƐƉĞĐƚƐWŽƐƚĞƌ WŽƐƚĞƌdŽƵƌ ϵ͗ϬϬÃʹ ϭϬ͗ϬϬà ACR Sessions PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ PM ACR-EULARWDZ'ƵŝĚĞůŝŶĞƐ DĞƚĂŝŶŇĂŵŵĂƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ ZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶKƐĐĂƌ^͘'ůƵĐŬDĞŵŽƌŝĂů >ĞĐƚƵƌĞƐŚŝƉ͗ŵĞƌŐŝŶŐdŚĞƌĂƉŝĞƐŝŶŽŶĞŝƐĞĂƐĞƐ͗ĞůůƵůĂƌ Basis and Challenges ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ ϭ͘ϬŚƌ͘ ϵ͗ϬϬÃʹ ϭϬ͗ϬϬà ARHP Sessions DLJĐŽďĂĐƚĞƌŝƵŵ/ŶĨĞĐƟŽŶƐŝŶ/ŵŵƵŶŽĐŽŵƉƌŽŵŝƐĞĚ WĂƟĞŶƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϰ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ RheumChat ^ƚĂƚƐŽŽƚĂŵƉ͗dŚĞWƌĞǀĂůĞŶĐĞZĂƟŽĂƐĂŶůƚĞƌŶĂƟǀĞ ƚŽƚŚĞKĚĚƐZĂƟŽĨŽƌƌŽƐƐͲ^ĞĐƟŽŶĂů^ƚƵĚŝĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϵ ϭ͘ϬŚƌ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 27 tracker TUESDAY, NOVEMBER 18, 2014 Time Title Meeting At-A-Glance Location CME/Hours of Participation ϭϬ͗ϬϬÃʹ Exhibits Ϯ͗ϯϬÖà džŚŝďŝƚ,ĂůůDŽƌŶŝŶŐ^ŶĂĐŬƌĞĂŬ;ϭϬ͗ϬϬʹϭϭ͗ϬϬÃͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϭϬ͗ϯϬÃʹ Exhibits ϭϭ͗ϭϱà /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϯϵͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ ϭϬ͗ϯϬÃʹ ZtŽƌŬƐŚŽƉƐ ϭϮ͗ϯϬÖà DƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽƵŶĚ;ϮϯϯͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ ZĞŶĂů,ŝƐƚŽƉĂƚŚŽůŽŐLJŝŶ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ ĂŶĚsĂƐĐƵůŝƟƐ;ϮϯϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϭ yͲZĂLJŚĂůůĞŶŐĞƐŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϮϯϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϰ Ϯ͘ϬŚƌƐ͘ ϭϭ͗ϬϬÃʹ ACR Sessions EŽŽŶ DĞƐĞŶĐŚLJŵĂů^ƚĞŵĞůůƐ͗ŝŽůŽŐLJĂŶĚhƐĞŝŶZŚĞƵŵĂƟĐ ŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϯ WƌŽƚĞĐƟŶŐŽŶĞ,ĞĂůƚŚŝŶWĞĚŝĂƚƌŝĐZŚĞƵŵĂƟĐ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ ŝƐĞĂƐĞƐ ϭ͘ϬŚƌ͘ ϭϭ͗ϬϬÃʹ ARHP Sessions EŽŽŶ /ŵŵƵŶŽůŽŐLJŽŽƚĂŵƉ///͗ƉƉůLJŝŶŐWƌŝŶĐŝƉůĞƐŽĨ E ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ /ŵŵƵŶŽůŽŐLJƚŽdƌĞĂƚŵĞŶƚĞĐŝƐŝŽŶƐ WĂƚŚǁĂLJƐƚŽZĞƐŝůŝĞŶĐĞ͗ŝŽƉƐLJĐŚŽƐŽĐŝĂůDĞĐŚĂŶŝƐŵƐĨŽƌ PM ͘ ͘ ͘ ͘ Ϯϱϱ ƚŚĞ'ĞŶĞƌĂƟŽŶŽĨWŽƐŝƟǀĞīĞĐƚŝŶŚƌŽŶŝĐWĂŝŶ WƌŽǀŝĚŝŶŐǀŝĚĞŶĐĞĨŽƌDŝĚͲ>ĞǀĞůWƌŽǀŝĚĞƌƐŝŶZŚĞƵŵĂƚŽůŽŐLJ WƌĂĐƟĐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ ϭ͘ϬŚƌ͘ ϭϭ͗ϬϬÃʹ ZWůĞŶĂƌLJ^ĞƐƐŝŽŶ///͗ŝƐĐŽǀĞƌLJϮϬϭϰ ϭϮ͗ϯϬÖà ďƐƚƌĂĐƚƐ;ηϮϳϴϭͲϮϳϴϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϭ͘ϱŚƌƐ͘ ϭϭ͗ϯϬÃʹ Exhibits ϭϮ͗ϭϱÖà /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϰϬϭͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ ϭϮ͗ϭϱÖÃʹ Exhibits ϭ͗ϬϬÖà /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϯϵͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ 28 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance Time TUESDAY, NOVEMBER 18, 2014 Location Title ϭϮ͗ϰϱÖÃʹ ACR Meet the Professor Sessions Ϯ͗ϭϱÖà ŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞ;ϬϳϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ŚĂůůĞŶŐŝŶŐĂƐĞƐŝŶKƐƚĞŽƉŽƌŽƐŝƐDĂŶĂŐĞŵĞŶƚ;ϬϳϮͿ͘ ͘ ͘ ͘ ͘ ͘ ƌLJƐƚĂů͗ŝĂŐŶŽƐŝƐĂŶĚDĂŶĂŐĞŵĞŶƚŽĨ'ŽƵƚ;ϬϳϯͿ PM ͘ ͘ ͘ ͘ ͘ ͘ EŽŶͲƐƵƌŐŝĐĂůdƌĞĂƚŵĞŶƚƐĨŽƌKƐƚĞŽĂƌƚŚƌŝƟƐ;ϬϳϰͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ KƐƚĞŽĂƌƚŚƌŝƟƐ͗hƉĚĂƚĞϮϬϭϰ;ϬϳϱͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ;ϬϳϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚLJ͗ŶhƉĚĂƚĞ;ϬϳϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐ͗>ƵƉƵƐEĞƉŚƌŝƟƐ;ϬϳϴͿ ͘ ͘ ͘ ͘ ͘ ͘ dĞŵƉŽƌĂůƌƚĞƌŝƟƐ;ϬϳϵͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ sĂĐĐŝŶĂƟŽŶƐĨŽƌWĂƟĞŶƚƐŽŶŝŽůŽŐŝĐdŚĞƌĂƉŝĞƐ;ϬϴϬͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭ͗ϬϬÖÃʹ Ϯ͗ϬϬÖà ϭ͗ϬϬÖÃʹ Ϯ͗ϬϬÖà ACR Sessions Clinical Issues Associated with the Use of PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ DĞƚŚŽƚƌĞdžĂƚĞ ,ĞŶĐŚ>ĞĐƚƵƌĞƐŚŝƉ͗tŚLJ^ƚĞƌŽŝĚƐtŽƌŬŝŶ^ŽŵĞ /ŶŇĂŵŵĂƚŽƌLJŝƐĞĂƐĞƐƵƚEŽƚŝŶKƚŚĞƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ EĞǁZĞŐƵůĂƚŽƌLJdĞůůƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ hŶĐŽǀĞƌŝŶŐƚŚĞZŽůĞŽĨŽŶŶĞĐƟǀĞdŝƐƐƵĞƐŝŶŚƌŽŶŝĐ>Žǁ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ĂĐŬWĂŝŶ͗&ƌŽŵĞĚƐŝĚĞƚŽĞŶĐŚƚŽĞĚƐŝĚĞ WĂŝŶĞ ;>ŽďďLJͿ KƟƐ ;>ŽďďLJͿ ,ĂŶĐŽĐŬ ;>ŽďďLJͿ ZĞǀĞƌĞ ;>ŽďďLJͿ ^ƚŽŶĞ ;>ŽďďLJͿ Webster ;>ŽďďLJͿ Adams ;DĞnjnjĂŶŝŶĞͿ ůĐŽƩ ;DĞnjnjĂŶŝŶĞͿ ŽƵŐůĂƐ ;DĞnjnjĂŶŝŶĞͿ &ĂŶĞƵŝů ;DĞnjnjĂŶŝŶĞͿ CME/Hours of Participation ϭ͘ϱŚƌƐ͘ ϭ͘ϬŚƌ͘ Ballroom East džŚŝďŝƚ,Ăůů Ϯϱϯ ϮϭϬ ARHP Sessions ƟŽůŽŐLJĂŶĚDĂŶĂŐĞŵĞŶƚŽĨWĞƌŝƉŚĞƌĂůEĞƵƌŽƉĂƚŚLJ ŝŶWĂƟĞŶƚƐǁŝƚŚZŚĞƵŵĂƟĐŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ PS ͘ ͘ ͘ ͘ Ϯϱϳ WŚĂƌŵĂĐŽƚŚĞƌĂƉLJ͗tŚĂƚ͛ƐEĞǁŝŶZŚĞƵŵĂƚŽůŽŐLJ ϭ͘ϬŚƌ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 29 tracker TUESDAY, NOVEMBER 18, 2014 Meeting At-A-Glance Location Time Title ϭ͗ϬϬÖÃʹ Ϯ͗ϬϬÖà ^ƚƵĚLJ'ƌŽƵƉƐ ZͲh>Z^ƚƵĚLJ'ƌŽƵƉ͗dŽǁĂƌĚĂEĞǁhŶĚĞƌƐƚĂŶĚŝŶŐ ŽĨDLJŽƐŝƟƐdŚƌŽƵŐŚ/ŶƚĞƌŶĂƟŽŶĂůŽůůĂďŽƌĂƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ƵƚŽĂŶƟďŽĚŝĞƐŝŶŝĂŐŶŽƐŝƐĂŶĚ&ŽůůŽǁͲhƉŽĨZŚĞƵŵĂƟĐ ŝƐĞĂƐĞƐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ĞŚĕĞƚ͛ƐŝƐĞĂƐĞ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ŝŽƐŝŵŝůĂƌƐŝŶZŚĞƵŵĂƚŽůŽŐLJ͗hƉĚĂƚĞ^ƚƵĚLJ'ƌŽƵƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ůŽƐŝŶŐƚŚĞ'ĂƉʹWƐŽƌŝĂƐŝƐƚŽWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ 'ůŽďĂůDƵƐĐƵůŽƐŬĞůĞƚĂů,ĞĂůƚŚ/ŶŝƟĂƟǀĞƐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ,ŝŐŚͲZĞƐŽůƵƟŽŶWĞƌŝƉŚĞƌĂůYƵĂŶƟƚĂƟǀĞŽŵƉƵƚĞĚ dŽŵŽŐƌĂƉŚLJ;,ZͲƉYdͿ/ŵĂŐŝŶŐŝŶƌƚŚƌŝƟƐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ :ƵǀĞŶŝůĞƌƚŚƌŝƟƐtŽƌŬŐƌŽƵƉ;:tͿ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ >ĂƟŶŵĞƌŝĐĂŶ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ EĞƵƌŽĞŶĚŽĐƌŝŶĞ/ŵŵƵŶŽůŽŐLJ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJ/ŵĂŐŝŶŐ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WŽůLJŵLJĂůŐŝĂZŚĞƵŵĂƟĐĂ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ^ƚƵĚLJ'ƌŽƵƉ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭ͗ϭϱÖÃʹ ϯ͗ϭϱÖà ZͬZ,WtŽƌŬƐŚŽƉƐ ĞƌŵĂƚŽƉĂƚŚŽůŽŐLJŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϮϯϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ DĂŐŶĞƟĐZĞƐŽŶĂŶĐĞ/ŵĂŐŝŶŐŽĨWĞƌŝƉŚĞƌĂů:ŽŝŶƚƐŝŶ ZŚĞƵŵĂƚŽůŽŐLJWƌĂĐƟĐĞ;ϮϯϳͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ DƵƐĐƵůŽƐŬĞůĞƚĂůhůƚƌĂƐŽŶŽŐƌĂƉŚLJ͗ĂƐŝĐ;ϮϯϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ dŚĞZŚĞƵŵĂƚŽůŽŐŝĐDƵƐĐƵůŽƐŬĞůĞƚĂů^ĐƌĞĞŶŝŶŐdžĂŵ͕ ǁŝƚŚŵƉŚĂƐŝƐŽŶKďũĞĐƟǀĞŝƐĞĂƐĞͲƐƉĞĐŝĮĐ DĞĂƐƵƌĞŵĞŶƚƐ;ϮϯϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ of Participation ϭϬϵ ϭϬϳ ϭϲϬ ϭϱϳ ϭϱϭ Ϯϱϰ Ϯϱϵ ϭϱϲ ϭϱϯ ϮϬϰ Ϯϱϲ ϭϬϰ ϭϬϮ ϭϲϭ Ϯ͘ϬŚƌƐ͘ ϭϱϰ ϭϱϵ ϭϱϮ ϭ͗ϯϬÖÃʹ Ϯ͗ϭϱÖà Exhibits /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ;ŽŽƚŚηϭϰϬϭͿ ^ĞĞƉĂŐĞϰϰĨŽƌƚŚĞ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ>ŝƐƟŶŐ͘ Ϯ͗ϬϬÖÃʹ Ϯ͗ϯϬÖà ACR Session ZƵƐŝŶĞƐƐDĞĞƟŶŐ Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ACR Sessions ĚƵĐĂƚŽƌ͗/ŶŶŽǀĂƟǀĞĚƵĐĂƚŽƌƐ͕EŽǀĞůdĞĐŚŶŝƋƵĞƐ͗ A ZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶ^ƉĞĐŝĂů^ĞƐƐŝŽŶ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ EŽǀĞůZĞŐƵůĂƚŽƌLJĞůů^ƵďƐĞƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ͗^ŬŝŶ͕ŶƚŚĞƐĞƐĂŶĚ:ŽŝŶƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ CME/Hours ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom West ϭ͘ϱŚƌƐ͘ 30 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance TUESDAY, NOVEMBER 18, 2014 Location CME/Hours Time Title Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ACR Concurrent Abstract Sessions Z>ĂƚĞͲďƌĞĂŬŝŶŐďƐƚƌĂĐƚ^ĞƐƐŝŽŶ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϭ͘ϱŚƌƐ͘ ;ηϮϳϴϳͲϮϳϵϭͿϮϬϭϰZŚĞƵŵĂƚŽůŽŐLJZĞƐĞĂƌĐŚ&ŽƵŶĚĂƟŽŶ ĚŵŽŶĚ>͘ƵďŽŝƐ͕D͕DĞŵŽƌŝĂů>ĞĐƚƵƌĞƐŚŝƉ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East ;ηϮϳϵϮͲϮϳϵϳͿŝŽůŽŐLJĂŶĚWĂƚŚŽůŽŐLJŽĨŽŶĞĂŶĚ:ŽŝŶƚ/͗ ŽŶĞZĞŵŽĚĞůŝŶŐŝŶ/ŶŇĂŵŵĂƟŽŶĂŶĚƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϮ ;ηϮϳϵϴͲϮϴϬϯͿLJƚŽŬŝŶĞƐ͕DĞĚŝĂƚŽƌƐ͕ĞůůͲĐĞůůĚŚĞƐŝŽŶ͕Ğůů dƌĂĸĐŬŝŶŐĂŶĚŶŐŝŽŐĞŶĞƐŝƐ/ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ ;ηϮϴϬϰͲϮϴϬϵͿDŝƐĐĞůůĂŶĞŽƵƐZŚĞƵŵĂƟĐĂŶĚ/ŶŇĂŵŵĂƚŽƌLJ ŝƐĞĂƐĞƐͬ/ŶŶĂƚĞ/ŵŵƵŶŝƚLJĂŶĚZŚĞƵŵĂƟĐŝƐĞĂƐĞ͗ƐƐĞƐƐŝŶŐ KƵƚĐŽŵĞƐŽĨ/ŶĨĞĐƟŽŶƐŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ ;ηϮϴϭϬͲϮϴϭϰͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐs͗ DŽƌƚĂůŝƚLJĂŶĚKƚŚĞƌKƵƚĐŽŵĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϴ ;ηϮϴϭϱͲϮϴϮϬͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ,ƵŵĂŶƟŽůŽŐLJĂŶĚ WĂƚŚŽŐĞŶĞƐŝƐ/͗DĞĐŚĂŶŝƐŵƐŽĨ:ŽŝŶƚĂŵĂŐĞʹ >ĞĞ͘,ŽǁůĞLJ͕^ƌ͘WƌŝnjĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ ;ηϮϴϮϭͲϮϴϮϲͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕ ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJs͗EŽǀĞůdŚĞƌĂƉŝĞƐŝŶ ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ>ĂƚĞŝŶĞǀĞůŽƉŵĞŶƚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϯ ;ηϮϴϮϳͲϮϴϯϮͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ IVʹůŝŶŝĐĂůƐƉĞĐƚƐdžŝĂů^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom West ;ηϮϴϯϯͲϮϴϯϴͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹClinical ƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚ͗EŽǀĞůdŚĞƌĂƉŝĞƐĨŽƌ^LJƐƚĞŵŝĐ>ƵƉƵƐ Erythematosus ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ ;ηϮϴϯϵͲϮϴϰϰͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹ,ƵŵĂŶ ƟŽůŽŐLJĂŶĚWĂƚŚŽŐĞŶĞƐŝƐ//͗WĂƚŚŽŐĞŶŝĐdĂƌŐĞƚƐ͕'ĞŶĞƟĐ sĂƌŝĂŶƚƐĂŶĚƉŽƉƚŽƐŝƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ ;ηϮϴϰϱͲϮϴϱϬͿdĞůůŝŽůŽŐLJĂŶĚdĂƌŐĞƚƐŝŶƵƚŽŝŵŵƵŶĞ ŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϵ ;ηϮϴϱϭͲϮϴϱϲͿsĂƐĐƵůŝƟƐ/// ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ACR/ARHP Combined Abstract Session ;ηϮϴϱϳͲϮϴϲϮͿZͬZ,WŽŵďŝŶĞĚďƐƚƌĂĐƚ^ĞƐƐŝŽŶ͗ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϬ ZĞŚĂďŝůŝƚĂƟŽŶ ϭ͘ϱŚƌƐ͘ Ϯ͗ϯϬÖÃʹ ϰ͗ϬϬÖà ARHP Sessions ƌŝĞĨĐƟŽŶWůĂŶŶŝŶŐ;WͿ͗DŽƟǀĂƟŽŶĂů/ŶƚĞƌǀŝĞǁŝŶŐ;D/Ϳ dĞĐŚŶŝƋƵĞƚŽŶŚĂŶĐĞWĂƟĞŶƚ^ĞůĨͲDĂŶĂŐĞŵĞŶƚĂŶĚ/ŵƉƌŽǀĞ PM Ed ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϰ KƵƚĐŽŵĞƐ KƐƚĞŽƉŽƌŽƐŝƐ͗ŵĞƌŐŝŶŐdƌĞĂƚŵĞŶƚƐŽƚŚWŚĂƌŵĂĐŽůŽŐŝĐĂů ĂŶĚEŽŶͲWŚĂƌŵĂĐŽůŽŐŝĐĂů ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ dŚĞWƐLJĐŚŽƐŽĐŝĂů/ŵƉĂĐƚĂŶĚdƌĞĂƚŵĞŶƚKƉƟŽŶƐĨŽƌWĂƟĞŶƚƐ ǁŝƚŚEĞƵƌŽƉƐLJĐŚŝĂƚƌŝĐ>ƵƉƵƐĂŶĚdŚĞŝƌĂƌĞŐŝǀĞƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ dƌĞĂƚŵĞŶƚŽŶƐŝĚĞƌĂƟŽŶƐŝŶŚƌŽŶŝĐWĂŝŶ ϭ͘ϱŚƌƐ͘ of Participation ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 31 tracker TUESDAY, NOVEMBER 18, 2014 Meeting At-A-Glance Location CME/Hours Time Title ϰ͗ϬϬÖÃʹ ϲ͗ϬϬÖà ZtŽƌŬƐŚŽƉƐ 'ĞƫŶŐůĞĐƚƌŽŶŝĐ,ĞĂůƚŚZĞĐŽƌĚƐZŝŐŚƚ;ϮϰϬͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϰ ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͗,ŽǁƚŽWĞƌĨŽƌŵ^ŬŝŶ^ĐŽƌĞƐ;ϮϰϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϮ hůƚƌĂƐŽƵŶĚ/ŶũĞĐƟŽŶ'ƵŝĚĂŶĐĞ;ϮϰϮͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϵ Ϯ͘ϬŚƌƐ͘ ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ACR Sessions ƵƚŽƉŚĂŐLJŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϬ ĞLJŽŶĚŶĂůŐĞƐŝĐƐ͗^ƚĂƚĞŽĨƚŚĞǀŝĚĞŶĐĞĨŽƌEƵƚƌŝƟŽŶ͕ sŝƚĂŵŝŶƐĂŶĚdžĞƌĐŝƐĞWƌĞƐĐƌŝƉƟŽŶƐŝŶKƐƚĞŽĂƌƚŚƌŝƟƐ DĂŶĂŐĞŵĞŶƚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϭϬ hƉĚĂƚĞŽŶ^ĂĨĞƚLJ/ƐƐƵĞƐŝŶƚŚĞdƌĞĂƚŵĞŶƚŽĨZŚĞƵŵĂƟĐ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ PS PM ŝƐĞĂƐĞƐʹ&ƌŽŵƚŚĞ&ĂŶĚĞLJŽŶĚ ϭ͘ϱŚƌƐ͘ ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ACR Concurrent Abstract Sessions ;ηϮϴϲϯͲϮϴϲϴͿŶƟƉŚŽƐƉŚŽůŝƉŝĚ^LJŶĚƌŽŵĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϮϴϲϵͲϮϴϳϰͿĞůůŝŽůŽŐLJĂŶĚdĂƌŐĞƚƐŝŶ ƵƚŽŝŵŵƵŶĞŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϮϴϳϱͲϮϴϴϬͿLJƚŽŬŝŶĞƐ͕DĞĚŝĂƚŽƌƐ͕ĞůůͲĐĞůůĚŚĞƐŝŽŶ͕Ğůů dƌĂĸĐŬŝŶŐĂŶĚŶŐŝŽŐĞŶĞƐŝƐ// ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ PM Ed ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϮϴϴϭͲϮϴϴϲͿĚƵĐĂƟŽŶ ;ηϮϴϴϳͲϮϴϵϮͿƉŝĚĞŵŝŽůŽŐLJĂŶĚWƵďůŝĐ,ĞĂůƚŚ/s͗ ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐWĂƚŚŽŐĞŶĞƐŝƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϮϴϵϯͲϮϴϵϴͿKƐƚĞŽĂƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐ//͗ KƐƚĞŽĂƌƚŚƌŝƟƐZŝƐŬ&ĂĐƚŽƌƐĂŶĚdŚĞƌĂƉŝĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϮϴϵϵͲϮϵϬϰͿWĞĚŝĂƚƌŝĐZŚĞƵŵĂƚŽůŽŐLJʹClinical and dŚĞƌĂƉĞƵƟĐƐƉĞĐƚƐ͗DŝƐĐĞůůĂŶĞŽƵƐWĞĚŝĂƚƌŝĐZŚĞƵŵĂƟĐ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ŝƐĞĂƐĞƐ ;ηϮϵϬϱͲϮϵϭϬͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹŶŝŵĂůDŽĚĞůƐ// ͘ ͘ ͘ ͘ ;ηϮϵϭϭͲϮϵϭϲͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐs/͗ /ŵƉĂĐƚŽĨdƌĞĂƚŵĞŶƚĂŶĚKƚŚĞƌ/ŶƚĞƌǀĞŶƟŽŶƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϮϵϭϳͲϮϵϮϮͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ,ƵŵĂŶƟŽůŽŐLJ ĂŶĚWĂƚŚŽŐĞŶĞƐŝƐ//͗ŝƚƌƵůůŝŶĂƟŽŶ͕ƵƚŽĂŶƟďŽĚŝĞƐ ĂŶĚ'ĞŶĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϮϵϮϯͲϮϵϮϴͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹ^ŵĂůůDŽůĞĐƵůĞƐ͕ ŝŽůŽŐŝĐƐĂŶĚ'ĞŶĞdŚĞƌĂƉLJs/͗ŝŽŵĂƌŬĞƌƐĂŶĚWƌĞĚŝĐƚŽƌƐ ŽĨZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐŝƐĞĂƐĞZĞƐƉŽŶƐĞĂŶĚ KƵƚĐŽŵĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϮϵϮϵͲϮϵϯϰͿ^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ/͗ůŝŶŝĐĂů WĞƌƐƉĞĐƟǀĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ;ηϮϵϯϱͲϮϵϰϬͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ VʹůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭ͘ϱŚƌƐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ ϭϬϰ ϭϬϵ ϭϬϳ ϭϱϲ Ϯϱϴ ϭϱϯ ϮϬϱ ϭϱϭ Ballroom East ϭϱϳ Ϯϱϯ ϭϬϮ Ballroom West of Participation 32 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance TUESDAY, NOVEMBER 18, 2014 Location Time Title ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ACR Meet the Professor Sessions ĚƵůƚ/ŶŇĂŵŵĂƚŽƌLJDLJŽƉĂƚŚLJ;ϬϴϭͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ĞŚĕĞƚ͛Ɛ^LJŶĚƌŽŵĞ;ϬϴϮͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ĂůĐŝƵŵƌLJƐƚĂůƌƚŚƌŝƟƐ;ϬϴϯͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ :ƵǀĞŶŝůĞĞƌŵĂƚŽŵLJŽƐŝƟƐ;ϬϴϰͿ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ DLJŽƉĂƚŚLJ͗/ƐƐƵĞƐŝŶŝĂŐŶŽƐŝƐĂŶĚdƌĞĂƚŵĞŶƚ;ϬϴϱͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WƌĞŐŶĂŶĐLJĂŶĚZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ;ϬϴϲͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ WƵůŵŽŶĂƌLJDĂŶŝĨĞƐƚĂƟŽŶƐŽĨZŚĞƵŵĂƟĐŝƐĞĂƐĞ;ϬϴϳͿ͘ ͘ ͘ ͘ ͘ ͘ ZĂLJŶĂƵĚ͛ƐĂŶĚŝŐŝƚĂů/ƐĐŚĞŵŝĂ;ϬϴϴͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗ŚĂůůĞŶŐŝŶŐĂƐĞƐ;ϬϴϵͿ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ dĞŵƉŽƌĂůƌƚĞƌŝƟƐ;ϬϵϬͿ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ARHP Sessions DƵůƟĚŝƐĐŝƉůŝŶĂƌLJDĂŶĂŐĞŵĞŶƚŽĨƚŚĞ:ƵǀĞŶŝůĞ/ĚŝŽƉĂƚŚŝĐ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ƌƚŚƌŝƟƐWĂƟĞŶƚ WĂƟĞŶƚͲZĞƉŽƌƚĞĚKƵƚĐŽŵĞƐĂƚĂĨŽƌŽŵƉĂƌĂƟǀĞ īĞĐƟǀĞŶĞƐƐZĞƐĞĂƌĐŚŝŶƌƚŚƌŝƟƐĂƌĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ^ƚĂƚĞͲŽĨͲƚŚĞͲƌƚ/ŶƚĞƌǀĞŶƟŽŶĂůZĞĐŽŵŵĞŶĚĂƟŽŶƐĨŽƌ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ŚƌŽŶŝĐ>ŽǁĂĐŬWĂŝŶ ^ƵĐĐĞƐƐĨƵůŐŝŶŐŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϰ͗ϯϬÖÃʹ ϲ͗ϬϬÖà ARHP Concurrent Abstract Sessions ;ηϮϵϰϭͲϮϵϰϲͿƉŝĚĞŵŝŽůŽŐLJͬWƵďůŝĐ,ĞĂůƚŚ ϲ͗ϯϬÖÃʹ ϵ͗ϯϬÖà /ŶĚƵƐƚƌLJͲ^ƵƉƉŽƌƚĞĚ^LJŵƉŽƐŝĂ ^ĞĞƉƌŽŐƌĂŵŬƉĂŐĞϮϯϵŽƌŶŶƵĂůDĞĞƟŶŐƉƉĨŽƌƚŚĞ ůŝƐƚŽĨƐLJŵƉŽƐŝĂ͘ WĂŝŶĞ ;>ŽďďLJͿ KƟƐ ;>ŽďďLJͿ ,ĂŶĐŽĐŬ ;>ŽďďLJͿ ZĞǀĞƌĞ ;>ŽďďLJͿ ^ƚŽŶĞ ;>ŽďďLJͿ Webster ;>ŽďďLJͿ Adams ;DĞnjnjĂŶŝŶĞͿ ůĐŽƩ ;DĞnjnjĂŶŝŶĞͿ ŽƵŐůĂƐ ;DĞnjnjĂŶŝŶĞͿ &ĂŶĞƵŝů ;DĞnjnjĂŶŝŶĞͿ CME/Hours of Participation ϭ͘ϱŚƌƐ͘ ϭ͘ϱŚƌƐ͘ Ϯϱϱ Ϯϱϲ Ϯϱϳ ϮϬϰ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϰ ϭ͘ϱŚƌƐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ session 33 tracker WEDNESDAY, NOVEMBER 19, 2014 Meeting At-A-Glance WEDNESDAY, NOVEMBER 19, 2014 Location CME/Hours Time Title ϳ͗ϬϬÃʹ ϭ͗ϬϬÖà ZͬZ,WZĞŐŝƐƚƌĂƟŽŶ džŚŝďŝƚ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ >ĞǀĞů;ĂƐƚ ZĞŐŝƐƚƌĂƟŽŶͿ ϳ͗ϯϬÃʹ ϴ͗ϯϬà ACR Sessions ϭ͘ϬŚƌ͘ ŽͲ^ƟŵƵůĂƟŽŶWĂƚŚǁĂLJƐ͗dŚĞƌĂƉĞƵƟĐKƉƉŽƌƚƵŶŝƟĞƐĨŽƌƚŚĞ ZŚĞƵŵĂƟĐŝƐĞĂƐĞƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ ZŚĞƵŵĂƚŽůŽŐLJZŽƵŶĚƵƉ͗,ŝŐŚůŝŐŚƚƐĨƌŽŵƚŚĞϮϬϭϰŶŶƵĂů DĞĞƟŶŐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East ϳ͗ϯϬÃʹ ϴ͗ϯϬà ARHP Sessions WŚLJƐŝĐĂůĂŶĚKĐĐƵƉĂƟŽŶĂůdŚĞƌĂƉLJĨŽƌ:ƵǀĞŶŝůĞ ĞƌŵĂƚŽŵLJŽƐŝƟƐ͗dƌĞĂƚŵĞŶƚWůĂŶŶŝŶŐĂŶĚĂƐĞ Pd PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ WƌĞƐĞŶƚĂƟŽŶƐ ZŚĞƵŵĂƟĐDĂŶŝĨĞƐƚĂƟŽŶƐŽĨDĂůŝŐŶĂŶĐLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ ϭ͘ϬŚƌ͘ ϵ͗ϬϬÃʹ ϭϬ͗ϯϬà ACR Sessions ŽŵƉůĞŵĞŶƚŝŶZŚĞƵŵĂƟĐŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ DŽǀŝŶŐdŽǁĂƌĚWĞƌƐŽŶĂůŝnjĞĚDĞĚŝĐŝŶĞĨŽƌ^LJƐƚĞŵŝĐ>ƵƉƵƐ ƌLJƚŚĞŵĂƚŽƐƵƐDĂŶĂŐĞŵĞŶƚ͗&ƌŽŵĞŶĐŚƚŽĞĚƐŝĚĞ ͘ ͘ ͘ ͘ WƌŝŵĂƌLJŶŐŝŝƟƐŽĨƚŚĞĞŶƚƌĂůEĞƌǀŽƵƐ^LJƐƚĞŵĂŶĚ /ƚƐDŝŵŝĐƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭ͘ϱŚƌƐ͘ ͶĚĞŶŽƚĞƐtĞƐƟŶtĂƚĞƌĨƌŽŶƚƌŽŽŵůŽĐĂƟŽŶ Ϯϱϯ Ballroom East Ballroom West of Participation 34 2014 ACR /A R H P A n n u a l M e e t i n g Meeting At-A-Glance WEDNESDAY, NOVEMBER 19, 2014 Location CME/Hours Time Title ϵ͗ϬϬÃʹ ϭϬ͗ϯϬà ACR Concurrent Abstract Sessions ;ηϮϵϰϳͲϮϵϱϮͿŝŽůŽŐLJĂŶĚWĂƚŚŽůŽŐLJŽĨŽŶĞĂŶĚ:ŽŝŶƚ//͗ ĂƌƟůĂŐĞŝŽůŽŐLJĂŶĚ^LJŶŽǀŝĂůĐƟǀĂƟŽŶ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϲϬ ;ηϮϵϱϯͲϮϵϱϴͿ'ĞŶĞƟĐƐ͕'ĞŶŽŵŝĐƐĂŶĚWƌŽƚĞŽŵŝĐƐ//͗ 'ĞŶĞƟĐƐŽĨƵƚŽŝŵŵƵŶŝƚLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϯ ;ηϮϵϱϵͲϮϵϲϰͿDĞƚĂďŽůŝĐĂŶĚƌLJƐƚĂůƌƚŚƌŽƉĂƚŚŝĞƐ//͗ DĞĐŚĂŶŝƐŵƐŽĨŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϰ ;ηϮϵϲϱͲϮϵϳϬͿWĂŝŶ͗ĂƐŝĐĂŶĚůŝŶŝĐĂůƐƉĞĐƚƐ//ͬKƌƚŚŽƉĞĚŝĐƐ͕ PM ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϬϳ >ŽǁĂĐŬWĂŝŶĂŶĚZĞŚĂďŝůŝƚĂƟŽŶ ;ηϮϵϳϭͲϮϵϳϲͿZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐʹůŝŶŝĐĂůƐƉĞĐƚƐs//͗ EĞǁƐƉĞĐƚƐŽĨDŽŶŝƚŽƌŝŶŐŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϴ ;ηϮϵϳϳͲϮϵϴϮͿ^ũƂŐƌĞŶ͛Ɛ^LJŶĚƌŽŵĞ//͗/ŶƐŝŐŚƚƐŝŶƚŽ WĂƚŚŽƉŚLJƐŝŽůŽŐLJ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϳ ;ηϮϵϴϯͲϮϵϴϴͿ^ƉŽŶĚLJůŽĂƌƚŚƌŽƉĂƚŚŝĞƐĂŶĚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ VIʹ/ŵĂŐŝŶŐĂŶĚŝŽŵĂƌŬĞƌƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϮϬϱ ;ηϮϵϴϵͲϮϵϵϰͿ^LJƐƚĞŵŝĐ>ƵƉƵƐƌLJƚŚĞŵĂƚŽƐƵƐʹ ůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdƌĞĂƚŵĞŶƚ͗E^ĂŶĚKƚŚĞƌůŝŶŝĐĂů ƐƉĞĐƚƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ ;ηϮϵϵϱͲϯϬϬϬͿ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐĂŶĚ ZĂLJŶĂƵĚ͛ƐʹůŝŶŝĐĂůƐƉĞĐƚƐĂŶĚdŚĞƌĂƉĞƵƟĐƐ///͗hƉĚĂƚĞƐŝŶ WƌĞĚŝĐƚŽƌƐĂŶĚKƵƚĐŽŵĞƐŝŶ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϭ ;ηϯϬϬϭͲϯϬϬϲͿ^LJƐƚĞŵŝĐ^ĐůĞƌŽƐŝƐ͕&ŝďƌŽƐŝŶŐ^LJŶĚƌŽŵĞƐ ĂŶĚZĂLJŶĂƵĚ͛ƐʹWĂƚŚŽŐĞŶĞƐŝƐ͕ŶŝŵĂůDŽĚĞůƐĂŶĚ 'ĞŶĞƟĐƐ// ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϭϱϲ ϭ͘ϱŚƌƐ͘ ϵ͗ϬϬÃʹ ϭϬ͗ϯϬà ARHP Sessions džĞƌĐŝƐĞĚŚĞƌĞŶĐĞŝŶƌƚŚƌŝƟƐ͗dŚĞZŽůĞ of Technology ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϲ EŽƚŚŝŶŐďŽƵƚhƐtŝƚŚŽƵƚhƐ͗ŶŐĂŐŝŶŐWĂƟĞŶƚƐŝŶ PS ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ Rheumatology Research ϭ͘ϱŚƌƐ͘ ϵ͗ϬϬÃʹ ϭϬ͗ϯϬà ARHP Concurrent Abstract Sessions ;ηϯϬϬϳͲϯϬϭϮͿůŝŶŝĐĂůWƌĂĐƟĐĞͬWĂƟĞŶƚĂƌĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϳ PM Ed ͘ ͘ ͘ ͘ Ϯϱϵ ;ηϯϬϭϯͲϯϬϭϴͿ/ŶŶŽǀĂƟŽŶƐŝŶZŚĞƵŵĂƚŽůŽŐŝĐĂƌĞ ϭ͘ϱŚƌƐ͘ of Participation session 35 tracker WEDNESDAY, NOVEMBER 19, 2014 Time Meeting At-A-Glance Location Title ϭϭ͗ϬϬÃʹ ACR Session EŽŽŶ /ŶŇĂŵŵĂƟŽŶĂŶĚƚŚĞƌŽƚŚƌŽŵďŽƐŝƐ CME/Hours of Participation ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ džŚŝďŝƚ,Ăůů ϭ͘ϬŚƌ͘ ϭϭ͗ϬϬÃʹ ACR Sessions ϭϮ͗ϯϬÖà ϭ͘ϱŚƌƐ͘ ĚǀĂŶĐĞƐŝŶDŽůĞĐƵůĂƌWƌŽĮůŝŶŐĂŶĚZĞůĞǀĂŶĐĞƚŽ ƵƚŽŝŵŵƵŶĞŝƐĞĂƐĞ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ϱϮ EŽŶͲZĂĚŝŽŐƌĂƉŚŝĐdžŝĂů^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ͗dŚĞŽŶƚƌŽǀĞƌƐLJŽĨ ŝĂŐŶŽƐŝƐĂŶĚKƉƟŵĂůdƌĞĂƚŵĞŶƚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ballroom East ϭϭ͗ϬϬÃʹ ARHP Session ϭϮ͗ϯϬÖà tŽƌŬĂŶĚtŽƌŬĞƌ,ĞĂůƚŚ͗ĂƐLJĐĐŽŵŵŽĚĂƟŽŶƐ<ĞĞƉ WĞŽƉůĞtŝƚŚƌƚŚƌŝƟƐŵƉůŽLJĞĚ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ ͘ Ϯϱϱ ϭ͗ϬϬÖÃʹ ϰ͗ϬϬÖà /ŶĚƵƐƚƌLJͲ^ƵƉƉŽƌƚĞĚWŽƐƚDĞĞƟŶŐ^LJŵƉŽƐŝĂ ^ĞĞƉƌŽŐƌĂŵŬƉĂŐĞϮϯϵŽƌŶŶƵĂůDĞĞƟŶŐƉƉĨŽƌƚŚĞ ůŝƐƚŽĨƐLJŵƉŽƐŝĂ͘ ϭ͘ϱŚƌƐ͘ 36 2014 ACR /A R H P A n n u a l M e e t i n g MAP #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFS meeting level 1 Boardroom and .FFUJOH3PPNT 6 Nursing Mothers Room 7 Prayer Room SW Lobby C 8 Restaurant Reservations & Visitor Information SW Lobby B2 9 Shuttle Bus Open to Exhibit Hall C (Below) Service Corridor 109 109 108 107 107 107 106 B A C B A Southwest Pre-function Industry-Supported Symposia Information Southeast Pre-function Skybridge First Aid 5 162 162 161 160 160 160 159 B A C B A 10 Technology Center Recharge Area West Side Drive Bar Wicked Good Market Open to Exhibit Hall B (Below) ATM Center East Pre-function 158 157 157 157 156 156 156 155 C B A C B A Skybridge Northwest Pre-function 105 104 104 104 103 102 102 101 C B A B A First Aid Business Center Service Corridor Open to Exhibit Hall A (Below) Service Corridor Northeast Pre-function 154 153 153 153 152 151 151 150 C B A B A ATM Outtakes 1 North Lobby to Entrance Plaza Stop 3 5 8 10 NW Corner Pre-function NE Corner Pre-function 4 11 Visitor Information East Side Drive 2 Concierge Center 4 SE Lobby B2 NW Lobby A NE Lobby A Coat/Baggage Check 3 SE Lobby C NW Lobby B1 NE Lobby B1 Business Center 2 7 9 9 1 6 Foundation Donors’ Lounge 3 Newsroom 4 Speaker Ready Room 213 261 Southwest Lobby Skybridge (Level 1) 212 211 Southwest Pre-function 210 210 210 C B A (Ballroom 210) Service Corridor Open to Exhibit Hall B (Below) Service Corridor Southeast Pre-function 209 208 Northwest Lobby Skybridge (Level 1) Northeast Lobby 205 B 205 A 204 204 203 B A Service Corridor 205 C Northwest Pre-function 207 206 206 B A Open to Exhibit Hall A (Below) West Boardroom Pre-function East BCMC Pre-function BCMC Sales Dept. North Lobby (Below) Bridge Boardroom Suite 201,202 Kitchen Storage Kitchen Bakery Skybridge Access Catering Office 253 252 252 251 B A A Service Corridor 253 B Northeast Pre-function 255 254 254 253 B A C NW Corner Pre-function NE Corner Pre-function 3 260 259 259 258 258 258 257 257 256 B A B A C B A 4 (Outside) 2 Southeast Lobby 1 Open to Exhibit Hall C (Below) ACR Office Lost and Found (Outside) 1 37 session tracker #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFSMAP meeting level 2 Boardroom and .FFUJOH3PPNT Entrance Plaza (Below) 2 38 2014 ACR /A R H P A n n u a l M e e t i n g MAP #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFS Ballroom Level Skybridge (Level 1) Low Roof (Outside) Exhibit Hall B (Below) Skybridge (Level 1) Exhibit Hall A (Below) Finishing Kitchen Green Room Lobby Ballroom West Ballroom Lobby Ballroom East Pre-function 2 1 3 Attendee Lounge 2 Late-breaking Abstracts 3 Opening Reception Exhibit Hall C (Below) Low Roof (Outside) Skybridge Access (Level 2) 3 1 session tracker #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFSMAP Exhibit Level Exhibit Hall A Exhibit Hall Skybridge (Level 1 Access) SE Lobby B2 Skybridge (Level 1 Access) 3 Poster Hall SE Lobby C East Registration 4 Session Room Session Room – Opening Lecture and Awards – Plenary Sessions I, II, III Exhibit Hall B 4 Exhibit Hall C Registration – Hotel Reservations – Membership Booth – Ribbon Distribution 051 050 3 052 A Poster Hall 052 B 2 ATM Exhibit Hall Discovery Center (Booth #731) – Career/Connection – Foundation Booth – Simple Tasks – Innovation Theaters A and B – Wi-Fi Way – Recharge Area Southeast Pre-function 1 NE Lobby B1 NE Lobby A 2 1 39 40 2014 ACR /A R H P A n n u a l M e e t i n g MAP #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFS ExhibitHall Entrance Exhibitor Lounge Exhibitor Suite A Snack Area Exhibitor Suite B 359 Innovation Theater A Exhibitor V X Suite U W 139 655 649 643 Exhibitor Exhibitor F Suite G Suite H 747 846 743 842 731 639 738 631 727 826 1039 1138 1055 1061 1160 Exhibitor Exhibitor L Suite I Suite J K 1060 959 1058 1056 955 1054 943 ACR Discovery Center 627 726 WiFi Way 1015 1114 919 1013 7 8 Food Court 6 10 11 13 1011 1110 1014 1 5 9 Exhibit Hall A 911 1010 1012 611 614 511 610 513 612 Exhibitor Exhibitor Exhibitor Suite C Suite D Suite E 457 447 439 421 514 411 510 401 WiFi Way 333 432 WiFi Way 232 329 428 331 430 229 230 327 426 228 226 325 424 323 422 224 221 321 222 319 418 301 400 402 311 410 313 315 414 220 211 201 203 302 205 304 218 212 210 Networking Lounge 101 2 3 4 1451 1339 1329 Exhibitor Suite T 1580 1561 1421 1401 1551 1547 1529 1527 1525 1521 1519 1517 Innovation Theater B 1429 1447 1546 1548 1457 1556 1557 1554 1555 1459 1558 1559 R Exhibitor Q Suite S 1347 1328A 1325 1324 1319 1301 1400 1402 1305 1404 1310 1328 WiFi Way 1346 Networking Lounge 1255 N Exhibitor P M Suite O 1159 1147 1218 1139 1133 1111 1200 Main Entrance Entrance session 41 tracker #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFSMAP Exhibit Hall List of Exhibitors BOOTH |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resenius Kabi 1039 $MJOJDBMBOE&YQFSJNFOUBM 3IFVNBUPMPHZ 1301 '6+*'*-.4POP4JUF*OD 846 (&)FBMUIDBSF 421 (FOFOUFDI".FNCFSPG UIF3PDIF(SPVQ 842 (FO[ZNFB4BOPöDPNQBOZ 1339, 1548 (MBYP4NJUI,MJOF 311 )BXBJJBO.PPO 229 )PSJ[PO1IBSNB*OD 1421 )PTQJSB 1546 *NBHF"OBMZTJT 511 *NNDP%JBHOPTUJDT"5SJOJUZ #JPUFDI$PNQBOZ 1060 *OPWB%JBHOPTUJDT*OD 1138 $POUFYU.FEJB)FBMUI 959 $PSSPOB--$ 649 $SFBMUB1IBSNBDFVUJDBMT 643 $SFTDFOEP#JPTDJFODF*OD 1058 %JQMPNBU4QFDJBMUZ 1IBSNBDZ 221 &EBO 1110 &MTFWJFS 510 &.%4FSPOP*OD 210 "VUPJNNVOF%JTFBTFT "TTPDJBUJPO 315 &OPWBUJWF5FDIOPMPHJFT 1347 #BZFS)FBMUIDBSF 1447 &TBPUF/PSUI"NFSJDB 428 #FTTF.FEJDBM 327 &4$&0BTCM 2014 ACR /A R H P A n n u a l M e e t i n g MAP #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFS Exhibit Hall List of Exhibitors BOOTH | EXHIBITOR 410 JO1SBDUJDF3FTPVSDFT--$ 9 .&5&03 1114 0TTVS"NFSJDBT 8 *OUFSOBUJPOBM'PVOEBUJPOGPS "VUPJNNVOF"SUISJUJT 313 .FUSP.FEJDBM 1451 0UUP5SBEJOH*OD 1014 *OWFTUJHBUPS%BUBCBOL 1459 .JTTJPO1IBSNBDBM $PNQBOZ 955 0YGPSE*NNVOPUFD 411 *SPLP1IBSNBDFVUJDBMT--$ 1015 .JUFL4QPSUT.FEJDJOF 1012 0YGPSE6OJWFSTJUZ1SFTT 1139 +BOTTFO#JPUFDI*OD 726 .PEFSOJ[JOH.FEJDJOF 1402 1"*(& 911 +PIOT)PQLJOT 3IFVNBUPMPHZ 228 1"/-"3 +PVSOBMPG3IFVNBUPMPHZ 5IF 2 333 .PUIFS5P#BCZ1SFHOBODZ Studies conducted by 0SHBOJ[BUJPOPG5FSBUPMPHZ *OGPSNBUJPO4QFDJBMJTUT 10 1BUJFOU"DDFTT/FUXPSL Foundation 1547 -B-FUUSF%V3IVNBUPMPHVF &%*."3,4"/5& 639 1BUJFOU1PJOU¥ 611 1ö[FS*OD 402 2*"(&/ 513 2VFTU%JBHOPTUJDT 212 2VJOUJMFT 323 3+'BTFONZFS$FOUFSGPS $MJOJDBM*NNVOPMPHZ 1551 3BJOUSFF4ZTUFNT*OD 631 3%-3FGFSFODF-BCPSBUPSZ 1147 3FHFOFSPO1IBSNBDFVUJDBMT *OD 426 3IFVNB,OPXMFEHZ 1325 3IFVNBUPMPHZ/FXT 1054 3PUUBQIBSN-UE 424 .VMUJTQFDJBMUZ1IZTJDJBO 1BSUOFST 826 -BC$PSQ 414 NZ$.& 220 -FUUFSUP&EJUPS 3IFVNBUPMPHZ 321 /BUJPOBM%BUB#BOLGPS 3IFVNBUJD%JTFBTFT 1310, 1554 -JMMZ64"--$ 319 /BUJPOBM*OTUJUVUFPG"SUISJUJT BOE.VTDVMPTLFMFUBMBOE Skin Diseases 1160 -JQP4DJFODF 457 .BMMJODLSPEU"VUPJNNVOF 3BSF%JTFBTFTGPSNFSMZ 2VFTUDPS 1519 /BUJPOBM+FXJTI)FBMUI 1 /BUJPOBM-JCSBSZPG.FEJDJOF 1404 .#-*OUFSOBUJPOBM 205 /BUJPOBM4DMFSPEFSNB$PSF $FOUFST 610 .D,FTTPO4QFDJBMUZ)FBMUI 747 Neovacs 1521 .%$POGFSFODF&YQSFTT 1328, " ,1329, 1429 /PWBSUJT1IBSNBDFVUJDBMT $PSQPSBUJPO 1319 422 .FEBD1IBSNB*OD .FEJ/BUVSB 418 /:6-BOHPOF.FEJDBM$FOUFS /:6)PTQJUBMGPS+PJOU%JTFBTFT session tracker #PTUPO$POWFOUJPOBOE&YIJCJUJPO$FOUFSMAP Exhibit Hall List of Exhibitors BOOTH | EXHIBITOR 331 Scandinavian +PVSOBMPG 3IFVNBUPMPHZ 232 4DMFSPEFSNB'PVOEBUJPO 13 4DMFSPEFSNB3FTFBSDI Foundation 738 4*#0/& 432 4KÚHSFOT4ZOESPNF Foundation 1055 4PCJ*OD 218 4QPOEZMJUJT"TTPDJBUJPOPG "NFSJDB 1305 4QSJOHFS 439 6$#*OD 1200 5BLFEB1IBSNBDFVUJDBMT 64"*OD 222 6OJWFSTJUZPG"MBCBNBBU #JSNJOHIBN 230 5IF(PVU6SJD"DJE &EVDBUJPO4PDJFUZ 201 643IFVNBUPMPHZ 7 5IF.ZPTJUJT"TTPDJBUJPO 627 7BMVF#BTFE$BSFJO 3IFVNBUPMPHZ 1560 5IF3"$POOFDUJPO 5 7BTDVMJUJT'PVOEBUJPO 612 5IFSB5FTU-BCPSBUPSJFT*OD 1010 8JMFZ 1517 5POJY1IBSNBDFVUJDBMT 727 8PMUFST,MVXFS)FBMUI 614 54*)FBMUIDBSF 1400 ;JNNFS Introducing the ACR/ARHP ANNUAL MEETING 2014 ACR/ARHP Annual Meeting App! NOW AI AV LABLE! DOWNLOADING THE APP IS EASY! For iPhone, iPod Touch, and iPad users: From your handheld device, go to the iTunes App Store and search “ACR 2014” or “2014 ACR Annual Meeting” to locate the app. Click on the “free” button, which will take you to the install screen. Next, download the 2014 ACR/ARHP Annual Meeting App as you would any other application from the iTunes App Store. It’s that easy. For BlackBerry, Android, and all other web-enabled smartphones and tablets: Point your device’s browser to m.core-apps.com/tristar_acr14. On this web-based mobile site, you will be directed to the proper download version for your device type. Scan this QR code using your device’s barcode scanner application for easy download ACR 2014 Supported by AbbVie, the 2014 ACR/ARHP Annual Meeting App is compatible with iPhone, BlackBerry, and Android smartphones, as well as iPad and most tablets. Get 24-hour access to unique, on-the-go meeting information, maps, and networking. Features include: 3 Interactive program and course schedules 3 Customizable calendar and itinerary builder 3 Exhibitor listings and booth map 3 Social media interaction 3 Meeting alerts 44 2014 ACR /A R H P A n n u a l M e e t i n g Innovation Theater dŚĞƐĞŶŽŶͲDĂĐĐƌĞĚŝƚĞĚƉƌĞƐĞŶƚĂƟŽŶƐŚĂǀĞďĞĞŶƉůĂŶŶĞĚĂŶĚǁŝůůďĞŝŵƉůĞŵĞŶƚĞĚǁŝƚŚƚŚĞƌĞƋƵŝƌĞŵĞŶƚƐŽĨƚŚĞ& ĂŶĚĂƉƉůŝĐĂďůĞƐƚĂŶĚĂƌĚƐŽĨƚŚĞWŚZDŽĚĞŽŶ/ŶƚĞƌĂĐƟŽŶƐǁŝƚŚ,ĞĂůƚŚĐĂƌĞWƌŽĨĞƐƐŝŽŶĂůƐ͘ /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ /ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌ ĂĐŚŽĨƚŚĞĨŽůůŽǁŝŶŐ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌƉƌĞƐĞŶƚĂƟŽŶƐǁŝůůďĞŚĞůĚ in džŚŝďŝƚ,Ăůů;ŽŽƚŚηϭϯϵͿ͘ ĂĐŚŽĨƚŚĞĨŽůůŽǁŝŶŐ/ŶŶŽǀĂƟŽŶdŚĞĂƚĞƌƉƌĞƐĞŶƚĂƟŽŶƐǁŝůůďĞŚĞůĚ in džŚŝďŝƚ,Ăůů;ŽŽƚŚηϭϰϬϭͿ͘ ^hEz͕EKsDZϭϲ͕ϮϬϭϰ ^hEz͕EKsDZϭϲ͕ϮϬϭϰ ϭϬ͗ϯϬͲϭϭ͗ϭϱà ϭϭ͗ϯϬÃͲϭϮ͗ϭϱÖà hŶĚĞƌƐƚĂŶĚŝŶŐĂŶ/ŶĨƵƐŝŽŶdŚĞƌĂƉLJŝŶƚŚĞh͘^͘,ĞĂůƚŚĐĂƌĞ ^LJƐƚĞŵ͗&ŽĐƵƐŽŶīŽƌĚĂďŝůŝƚLJ dŚĞZŽůĞŽĨ/>ͲϲŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗tŚĂƚ,ĂǀĞtĞ >ĞĂƌŶĞĚ^ŽĨĂƌ͍ WƌĞƐĞŶƚĞĚďLJ:ĂŶƐƐĞŶŝŽƚĞĐŚ͕/ŶĐ͘ WƌĞƐĞŶƚĞĚďLJZĞŐĞŶĞƌŽŶWŚĂƌŵĂĐĞƵƟĐĂůƐ ϭϮ͗ϯϬͲϭ͗ϭϱÖà ϭ͗ϯϬͲϮ͗ϭϱÖà First in a New Class of JAK Inhibitors for the Treatment of DŽĚĞƌĂƚĞƚŽ^ĞǀĞƌĞZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ tŚĞŶ/ƐƚŚĞZŝŐŚƚdŝŵĞĨŽƌKZE/Π;ĂďĂƚĂĐĞƉƚͿ͍ WƌĞƐĞŶƚĞĚďLJWĮnjĞƌ͕/ŶĐ͘ WƌĞƐĞŶƚĞĚďLJƌŝƐƚŽůͲDLJĞƌƐ^ƋƵŝďď ϯ͗ϯϬͲϰ͗ϭϱÖà Ϯ͗ϯϬͲϯ͗ϭϱÖà ϮϬϭϰhƉĚĂƚĞ͗džĂŵŝŶŝŶŐƚŚĞdƌĞĂƚŵĞŶƚWĂƌĂĚŝŐŵŝŶZ KƚĞnjůĂΠ;ĂƉƌĞŵŝůĂƐƚͿĨŽƌƚŚĞdƌĞĂƚŵĞŶƚŽĨĚƵůƚƐtŝƚŚĐƟǀĞ WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ WƌĞƐĞŶƚĞĚďLJDĞĚĂĐWŚĂƌŵĂ͕/ŶĐ͘ WƌĞƐĞŶƚĞĚďLJĞůŐĞŶĞŽƌƉŽƌĂƟŽŶ DKEz͕EKsDZϭϳ͕ϮϬϭϰ DKEz͕EKsDZϭϳ͕ϮϬϭϰ ϭϬ͗ϯϬͲϭϭ͗ϭϱà ZŝƚƵdžĂŶΠ;ƌŝƚƵdžŝŵĂďͿĨŽƌƚŚĞdƌĞĂƚŵĞŶƚŽĨ'ƌĂŶƵůŽŵĂƚŽƐŝƐ tŝƚŚWŽůLJĂŶŐŝŝƟƐ;'WͿĂŶĚDŝĐƌŽƐĐŽƉŝĐWŽůLJĂŶŐŝŝƟƐ;DWͿ ǁŝƚŚhƉĚĂƚĞĚĂƚĂĨŽƌ'WͬDW WƌĞƐĞŶƚĞĚďLJ'ĞŶĞŶƚĞĐŚ͕ĂDĞŵďĞƌŽĨƚŚĞZŽĐŚĞ'ƌŽƵƉ ϭϭ͗ϯϬÃͲϭϮ͗ϭϱÖà sĞĐƚƌĂΠ͗ĞƩĞƌDĞĂƐƵƌĞĨŽƌWƌĞĚŝĐƟŶŐZĂĚŝŽŐƌĂƉŚŝĐ WƌŽŐƌĞƐƐŝŽŶŝŶZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͍ WƌĞƐĞŶƚĞĚďLJƌĞƐĐĞŶĚŽŝŽƐĐŝĞŶĐĞ͕/ŶĐ͘ ϭ͗ϯϬͲϮ͗ϭϱÖà ϭϮ͗ϯϬͲϭ͗ϭϱÖà ZŚĞƵŵĂƚŽůŽŐŝƐƚƐ͛WĞƌƐƉĞĐƟǀĞƐŽŶƚŚĞŝĂŐŶŽƐŝƐ and Treatment of CAPS and SJIA ^ĞƌŝŽƵƐ/ŶĨĞĐƟŽŶƐŝŶDŽĚĞƌĂƚĞůLJƚŽ^ĞǀĞƌĞůLJĐƟǀĞ ZŚĞƵŵĂƚŽŝĚƌƚŚƌŝƟƐ͗,ĞƉĂƟƟƐZĞĂĐƟǀĂƟŽŶ WƌĞƐĞŶƚĞĚďLJEŽǀĂƌƟƐWŚĂƌŵĂĐĞƵƟĐĂůƐ WƌĞƐĞŶƚĞĚďLJŵŐĞŶ͕/ŶĐ͘ Ϯ͗ϯϬͲϯ͗ϭϱÖà ϯ͗ϯϬͲϰ͗ϭϱÖà dŚĞEĞǁƌĂŽĨŝŽůŽŐŝĐdŚĞƌĂƉLJŝŶZŚĞƵŵĂƚŽůŽŐLJ WƌĞƐĞŶƚĞĚďLJĞůůƚƌŝŽŶ,ĞĂůƚŚĐĂƌĞŽ͕͘>d͘ dŚĞhƌŝĐĐŝĚ:ŽƵƌŶĞLJ͗&ƌŽŵWƵƌŝŶĞƚŽƌLJƐƚĂů WƌĞƐĞŶƚĞĚďLJƐƚƌĂĞŶĞĐĂ dh^z͕EKsDZϭϴ͕ϮϬϭϰ dh^z͕EKsDZϭϴ͕ϮϬϭϰ ϭϬ͗ϯϬͲϭϭ͗ϭϱà hŶĚĞƌƐƚĂŶĚŝŶŐƚŚĞZŽůĞŽĨƚŚĞ/>ͲϭϳZĞĐĞƉƚŽƌĂŶĚLJƚŽŬŝŶĞƐŝŶ WƐŽƌŝĂƟĐƌƚŚƌŝƟƐ WƌĞƐĞŶƚĞĚďLJŵŐĞŶ͕/ŶĐ͘ ϭϭ͗ϯϬͲϭϮ͗ϭϱà ^ĞƌƵŵϭϰͲϯͲϯɻ͗EŽǀĞůDĞĐŚĂŶŝƐƟĐŝŽŵĂƌŬĞƌŶĂďůĞƐĂDŽƌĞ ĐĐƵƌĂƚĞĂŶĚĂƌůŝĞƌŝĂŐŶŽƐŝƐŽĨZ WƌĞƐĞŶƚĞĚďLJYƵĞƐƚŝĂŐŶŽƐƟĐƐ ϭ͗ϯϬͲϮ͗ϭϱÖà ϭϮ͗ϭϱͲϭ͗ϬϬÖà ĚǀĂŶĐŝŶŐƚŚĞ^ĐŝĞŶĐĞŽĨŶĂůŐĞŶƐŝĂtŝƚŚ^ŽůƵDĂƚƌŝdžΠE^/Ɛ ĞŵLJƐƟĨLJŝŶŐŝŽƐŝŵŝůĂƌƐŝŶZŚĞƵŵĂƚŽůŽŐLJ ^ŽůƵDĂƚƌŝdžΠŝƐĂƚƌĂĚĞŵĂƌŬŽĨŝĞƵƟĐĂWƚLJ>ƚĚĂŶĚŝƐůŝĐĞŶƐĞĚƚŽ/ƌŽŬŽ͘ WƌĞƐĞŶƚĞĚďLJWĮnjĞƌ͕/ŶĐ͘ WƌĞƐĞŶƚĞĚďLJ/ƌŽŬŽWŚĂƌŵĂĐĞƵƟĐĂůƐ͕>> 45 Enbrel® (etanercept) Brief Summary SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION WARNINGS SERIOUS INFECTIONS AND MALIGNANCIES Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions and Adverse Reactions]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Enbrel should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: I Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Enbrel use and during therapy. Treatment for latent infection should be initiated prior to Enbrel use. I Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. I Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel. INDICATIONS AND USAGE Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older. Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used in combination with methotrexate (MTX) in patients who do not respond adequately to MTX alone. Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). Plaque Psoriasis Enbrel is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONS Enbrel should not be administered to patients with sepsis. WARNINGS AND PRECAUTIONS Serious Infections Patients treated with Enbrel are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease. Treatment with Enbrel should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. The risks and benefits of treatment should be considered prior to initiating therapy in patients: with chronic or recurrent infection; who have been exposed to tuberculosis; with a history of an opportunistic infection; who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or with underlying conditions that may predispose them to infection, such as advanced or poorly controlled diabetes [see Adverse Reactions]. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel. Enbrel should be discontinued if a patient develops a serious infection or sepsis. A patient who develops a new infection during treatment with Enbrel should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and appropriate antimicrobial therapy should be initiated. Tuberculosis Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving Enbrel, including patients who have previously received treatment for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel. Tuberculosis has developed in patients who tested negative for latent tuberculosis prior to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests for latent tuberculosis infection may be falsely negative while on therapy with Enbrel. Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with tuberculin skin testing should be considered a positive test result when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG). Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating antituberculosis therapy is appropriate for an individual patient. Tuberculosis should be strongly considered in patients who develop a new infection during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis. Invasive Fungal Infections Cases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel. For patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. When feasible, the decision to administer empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of antifungal therapy. In 38 Enbrel clinical trials and 4 cohort studies in all approved indications representing 27,169 patient-years of exposure (17,696 patients) from the United States and Canada, no histoplasmosis infections were reported among patients treated with Enbrel. Neurologic Events Treatment with TNF-blocking agents, including Enbrel, has been associated with rare (< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders [see Adverse Reactions]. Malignancies Lymphomas In the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared to control patients. During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, 2 lymphomas were observed among 3306 Enbrel-treated patients versus 0 among 1521 control patients (duration of controlled treatment ranged from 3 to 36 months). Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled and uncontrolled portions of clinical trials, representing approximately 12,845 patient-years of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than the rate of lymphoma expected in the general US population based on the Surveillance, Epidemiology, and End Results (SEER) Database. An increased rate of lymphoma up to several-fold has been reported in the RA patient population, and may be further increased in patients with more severe disease activity. Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36 months, representing approximately 4278 patient-years of therapy, the observed rate of lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the general population. No cases were observed in Enbrel- or placebo-treated patients during the controlled portions of these trials. Leukemia Cases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher risk (approximately 2-fold) than the general population for the development of leukemia. During the controlled portions of Enbrel trials, 2 cases of leukemia were observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated patients versus 0 among 2890 (0%) control patients (duration of controlled treatment ranged from 3 to 48 months). Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of leukemia was 0.03 cases per 100 patient-years. Other Malignancies Information is available from 10,953 adult patients with 17,123 patientyears and 696 pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies. For malignancies other than lymphoma and non-melanoma skin cancer, there was no difference in exposure-adjusted rates between the Enbrel and control arms in the controlled portions of clinical studies for all indications. Analysis of the malignancy rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general US population based on the SEER database and suggests no increase in rates over time. Whether treatment with Enbrel might influence the development and course of malignancies in adults is unknown. Melanoma and Non-melanoma skin cancer (NMSC) Melanoma and non-melanoma skin cancer has been reported in patients treated with TNF antagonists including etanercept. Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of melanoma was 0.043 cases per 100 patient-years. Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled clinical trials representing approximately 2669 patient-years of therapy, the observed rate of NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 control-treated patients representing 1077 patient-years. Among 1245 adult psoriasis patients treated with Enbrel in controlled clinical trials, representing approximately 283 patient-years of therapy, the observed rate of NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patient-years among 720 control-treated patients representing 156 patient-years. Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel. Periodic skin examinations should be considered for all patients at increased risk for skin cancer. Pediatric Patients Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at ≤ 18 years of age), including Enbrel. Approximately half the cases were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports. In clinical trials of 1140 pediatric patients representing 1927.2 patient-years of therapy, no malignancies, including lymphoma or NMSC, have been reported. Postmarketing Use In global postmarketing adult and pediatric use, lymphoma and other malignancies have been reported. Patients With Heart Failure Two clinical trials evaluating the use of Enbrel in the treatment of heart failure were terminated early due to lack of efficacy. One of these studies suggested higher mortality in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have been postmarketing reports of worsening of congestive heart failure (CHF), with and without identifiable precipitating factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports of new onset CHF, including CHF in patients without known preexisting cardiovascular disease. Some of these patients have been under 50 years of age. Physicians should exercise caution when using Enbrel in patients who also have heart failure, and monitor patients carefully. Hematologic Events Rare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. The causal relationship to Enbrel therapy remains unclear. Although no high-risk group has been identified, caution should be exercised in patients being treated with Enbrel who have a previous history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be considered in patients with confirmed significant hematologic abnormalities. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 10 9/L). While neutropenic, one patient developed cellulitis that resolved with antibiotic therapy. Hepatitis B Reactivation Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-blocking agents, including very rare cases (< 0.01%) with Enbrel, has been reported. In some instances, hepatitis B reactivation occurring in conjunction with TNFblocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to hepatitis B reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients previously infected with HBV and require treatment with Enbrel should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping Enbrel and initiating anti-viral therapy with appropriate supportive treatment. The safety of resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation. Allergic Reactions Allergic reactions associated with administration of Enbrel during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of Enbrel should be discontinued immediately and appropriate therapy initiated. Caution: The following components contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex: the needle cover of the prefilled syringe and the needle cover within the needle cap of the SureClick® autoinjector. Immunizations Live vaccines should not be given concurrently with Enbrel. It is recommended that pediatric patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating Enbrel therapy [see Drug Interactions]. Autoimmunity Treatment with Enbrel may result in the formation of autoantibodies [see Adverse Reactions] and, rarely (< 0.1%), in the development of a lupus-like syndrome or autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should be discontinued and the patient should be carefully evaluated. Immunosuppression TNF mediates inflammation and modulates cellular immune responses. TNF-blocking agents, including Enbrel, affect host defenses against infections. The effect of TNF inhibition on the development and course of malignancies is not fully understood. In a study of 49 patients with RA treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations [see Adverse Reactions]. Use in Wegener’s Granulomatosis Patients The use of Enbrel in patients with Wegener’s granulomatosis receiving immunosuppressive agents is not recommended. In a study of patients with Wegener’s granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) was associated with a higher incidence of non cutaneous solid malignancies and was not associated with improved clinical outcomes when compared with standard therapy alone [see Drug Interactions]. Use with Anakinra or Abatacept Use of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions]. Use in Patients with Moderate to Severe Alcoholic Hepatitis In a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar to patients treated with placebo at 1 month but significantly higher after 6 months. Physicians should use caution when using Enbrel in patients with moderate to severe alcoholic hepatitis. ADVERSE REACTIONS Across clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events [see Warnings and Precautions]. The most common adverse reactions with Enbrel were infections and injection site reactions. Other Adverse Reactions Table 3 summarizes adverse reactions reported in adult RA patients. The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA. Table 3. Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials Placebo Controlleda (Studies I, II, and a Phase 2 Study) Clinical Studies Experience Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis The data described below reflect exposure to Enbrel in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months. In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied. Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice. Infections Infections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other immunosuppressive agents. In controlled portions of trials, the types and severity of infection were similar between Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS and PsO patients. Rates of infections in RA and PsO patients are provided in Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis and influenza. In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/ Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical trials in PsO, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of serious infections was not increased in open-label extension trials and was similar to that observed in Enbrel- and placebo-treated patients from controlled trials. In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the US and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings and Precautions]. Injection Site Reactions In placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with Enbrel developed injection site reactions. In controlled trials in patients with PsO, 15% of patients treated with Enbrel developed injection site reactions during the first 3 months of treatment. All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given. Immunogenicity Patients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to etanercept. Antibodies to the TNF receptor portion or other protein components of the Enbrel drug product were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with Enbrel. In PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 weeks ranged from 3.6%–8.7% and were all non-neutralizing. The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The immunogenicity data of Enbrel beyond 120 weeks of exposure are unknown. The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of any antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to etanercept with the incidence of antibodies to other products may be misleading. Autoantibodies Patients with RA had serum samples tested for autoantibodies at multiple time points. In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer ≥ 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive antidouble-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In RA Study III, no pattern of increased autoantibody development was seen in Enbrel patients compared to MTX patients [see Warnings and Precautions]. Placebo (N = 152) Reaction Enbrelc (N = 349) Percent of Patients Infectiond (total) Upper Respiratory Infectionse Non-upper Respiratory Infections Injection Site Reactions Diarrhea Rash Pruritus Pyrexia Urticaria Hypersensitivity Active Controlledb (Study III) MTX (N = 217) Enbrelc (N = 415) Percent of Patients 39 30 50 38 86 70 81 65 15 21 59 54 11 37 18 43 9 2 1 – 1 – 8 3 2 3 – – 16 19 5 4 4 1 16 13 5 2 2 1 a Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms. Study duration of 2 years. Any dose. d Includes bacterial, viral, and fungal infections. e Most frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis, and influenza. b c In placebo-controlled PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group. Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II. Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of Clinical Trials (Studies I & II) Placebo (N = 359) Enbrela (N = 876) Reaction Percent of Patients Infectionb (total) Non-upper Respiratory Infections Upper Respiratory Infectionsc Injection Site Reactions Diarrhea Rash Pruritus Urticaria Hypersensitivity Pyrexia 28 14 a 27 12 17 17 6 15 2 1 2 – – 1 3 1 1 1 1 – Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC BIW doses. Includes bacterial, viral and fungal infections. Most frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis and sinusitis. b c Adverse Reactions in Pediatric Patients In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients [see Warnings and Precautions]. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae. In open-label clinical studies of children with JIA, adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported in older children. Postmarketing Experience Adverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure. Adverse reactions are listed by body system below: Blood and lymphatic pancytopenia, anemia, system disorders: leukopenia, neutropenia, thrombocytopenia, lymphadenopathy, aplastic anemia [see Warnings and Precautions] Cardiac disorders: congestive heart failure [see Warnings and Precautions] Gastrointestinal disorders: inflammatory bowel disease (IBD) General disorders: angioedema, chest pain Hepatobiliary disorders: autoimmune hepatitis, elevated transaminases, hepatitis B reactivation Immune disorders: macrophage activation syndrome, systemic vasculitis Musculoskeletal and lupus-like syndrome connective tissue disorders: Neoplasms benign, melanoma and non-melanoma skin malignant, and unspecified: cancers, merkel cell carcinoma [see Warnings and Precautions] Nervous system disorders: convulsions, multiple sclerosis, demyelination, optic neuritis, transverse myelitis, paresthesias [see Warnings and Precautions] Ocular disorders: uveitis, scleritis Respiratory, thoracic interstitial lung disease and mediastinal disorders: Skin and subcutaneous tissue disorders: cutaneous lupus erythematous, cutaneous vasculitis (including leukocytoclastic vasculitis), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all sub-types including pustular and palmoplantar) Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use. DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see Warnings and Precautions]. Immune-Modulating Biologic Products In a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) [see Warnings and Precautions] and did not result in higher ACR response rates compared to Enbrel alone. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 10 9/L). In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit [see Warnings and Precautions]. Cyclophosphamide The use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended [see Warnings and Precautions]. Sulfasalazine Patients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical significance of this observation is unknown. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Category B Pregnancy Surveillance Program There is a Pregnancy Surveillance Program that monitors outcomes in women exposed to Enbrel during pregnancy. Women who become pregnant during Enbrel treatment are encouraged to enroll. Patients or their physicians should call 1-800-77-AMGEN (1-800-772-6436) to enroll. Risk Summary There are no adequate and well controlled studies in pregnant women. Based on limited data, etanercept concentration in cord blood at the time of delivery showed that etanercept crossed the placenta in small amounts. Developmental toxicity studies have been performed in rats and rabbits at doses ranging from 60- to 100-fold higher than the human dose and have revealed no evidence of harm to the fetus due to Enbrel. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Human Data Three case reports showed that cord blood levels of etanercept at delivery in infants, born to mothers administered etanercept during pregnancy, were between 3 and 32% of the maternal serum level. Nursing Mothers Limited data from published literature show that etanercept is present in low levels in human milk and minimally absorbed by a breastfed infant. Caution should be exercised when Enbrel is administered to a nursing woman. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Enbrel and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition. Women who choose to continue Enbrel treatment while nursing are encouraged to enroll in Amgen’s Lactation Surveillance Program. Patients or their physicians should call 1-800-77-AMGEN (1-800-772-6436) to enroll. Pediatric Use Enbrel has not been studied in children < 2 years of age with JIA. The safety and efficacy of Enbrel in pediatric patients with PsO have not been studied. Rare (< 0.1%) cases of IBD have been reported in JIA patients receiving Enbrel, which is not effective for the treatment of IBD [see Adverse Reactions (6.2)]. The clinical significance of infant exposure to Enbrel in utero is unknown. The safety of administering live or live-attenuated vaccines in exposed infants is unknown. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to exposed infants. Geriatric Use A total of 480 RA patients ages 65 years or older have been studied in clinical trials. In PsO randomized clinical trials, a total of 138 out of 1965 subjects treated with Enbrel or placebo were age 65 or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but the number of geriatric PsO subjects is too small to determine whether they respond differently from younger subjects. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly. Use in Diabetics There have been reports of hypoglycemia following initiation of Enbrel therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients. Rx Only. This brief summary is based on ENBREL prescribing information v.53: 11/2013 US License Number 1132 © 1998 – 2013 Immunex Corporation. All rights reserved. US Patent Nos. 7,915,225; 5,605,690; Re. 36,755. For more information please call 1-888-436-2735 or visit www.enbrel.com © 2013 Amgen Inc., Thousand Oaks, CA 91320 All rights reserved. 60077-R5-V3 IMPORTANT SAFETY INFORMATION SERIOUS INFECTIONS Patients treated with ENBREL (etanercept) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefi ts of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL. In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis patients. The role of TNF blocker therapy in the development of malignancies is unknown. Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population. Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer. Pediatric Patients In patients who initiated therapy at ≤18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin’s and non-Hodgkin’s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants. NEUROLOGIC EVENTS Treatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been ©2014 Amgen Inc., Thousand Oaks, CA 91320 All rights reserved. 81818-R1-V1 reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders. CONGESTIVE HEART FAILURE Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored. HEMATOLOGIC EVENTS Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed. HEPATITIS B REACTIVATION Reactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including ENBREL. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ENBREL in these patients. ALLERGIC REACTIONS Allergic reactions associated with administration of ENBREL during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated. IMMUNIZATIONS Live vaccines should not be administered to patients on ENBREL. JIA patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, consider temporary discontinuation of ENBREL and prophylactic treatment with Varicella Zoster Immune Globulin. AUTOIMMUNITY Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops. WEGENER’S GRANULOMATOSIS PATIENTS The use of ENBREL in patients with Wegener’s granulomatosis receiving immunosuppressive agents (eg, cyclophosphamide) is not recommended. MODERATE TO SEVERE ALCOHOLIC HEPATITIS Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis. ADVERSE EVENTS The most commonly reported adverse events in RA clinical trials were injection site reaction, infection, and headache. In clinical trials of all other adult indications, adverse events were similar to those reported in RA clinical trials. DRUG INTERACTIONS The use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in antidiabetic medication in some of these patients. Please see Brief Summary of Prescribing Information on the preceding pages. References: 1. Enbrel® (etanercept) Prescribing Information, Immunex Corporation, Thousand Oaks, Calif. November 2013. 2. Data on file, Amgen; #1 Biologic for Rheumatologists: May 2, 2014. 3. Data on file, Amgen; TEMPO CSR 57599 3 yr Clinical: June 21, 2005. In moderately to severely active rheumatoid arthritis (RA) Help patients get back to many of the activities they love ACTIVE ; MOVEMENT ; ENABLE ; EXPLORE ; SUPPORT ; ENBREL ENBREL + MTX achieved significant improvements in physical function vs MTX alone as measured by HAQ-DI by Week 2 and out to Year 31* Whether your patients are practicing their putt, spending time with family, or walking their dog, ENBREL has been a symbol of change for your patients with moderate to severe RA. Since 1998, ENBREL was the first and is still the only FDA-approved soluble TNF receptor treatment for appropriate patients. Because of you, ENBREL is the #1 prescribed biologic by rheumatologists today.2† ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone. Prescription ENBREL is administered by injection. Important Safety Considerations: ENBREL suppresses the immune system and has been associated with serious and sometimes fatal infections, including TB and other opportunistic infections. Other serious and sometimes fatal adverse events including malignancies, neurologic events, hematologic events, congestive heart failure, hepatitis B reactivation, allergic reactions, lupus-like syndrome and autoimmune hepatitis have also been reported. ENBREL is contraindicated in patients with sepsis. Please see additional Important Safety Information and Brief Summary on preceding pages. *In the TEMPO study, mean HAQ scores at baseline, week 2, and year 3 were 1.7, 1.5, and 1.1 in the MTX arm (n = 228) and 1.8, 1.3, and 0.8 in the ENBREL + MTX arm (n = 231), respectively.3 HAQ-DI = Health Assessment Questionnaire-Disability Index. †6-month total of IMS monthly NPA prescription data by rheumatologists. These data include only dispensed total scripts. Visit Booth #943 to see how you can help patients get back to many of the activities they love. Enbrel® and the Enbrel® logo are registered trademarks of Immunex Corporation.
© Copyright 2024